

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	EXCTD-35239.313
		Application Number	
Title of Invention	FECAL SAMPLE PROCESSING AND ANALYSIS COMPRISING DETECTION OF BLOOD		
The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76. This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the document may be printed and included in a paper filed application.			

Secrecy Order 37 CFR 5.2:

☐	Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to 37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)
--------------------------	---

Inventor Information:

Inventor 1					Remove
Legal Name					
Prefix	Given Name	Middle Name	Family Name	Suffix	
	Joost		Louwagie		
Residence Information (Select One) ☐ US Residency ☒ Non US Residency ☐ Active US Military Service					
City	Dornach		Country of Residence ⁱ	CH	
Mailing Address of Inventor:					
Address 1		c/o Exact Sciences Corporation			
Address 2		5505 Endeavor Lane			
City	Madison		State/Province	WI	
Postal Code	53719		Country ⁱ	US	
All Inventors Must Be Listed - Additional Inventor Information blocks may be generated within this form by selecting the Add button.					

Correspondence Information:

Enter either Customer Number or complete the Correspondence Information section below. For further information see 37 CFR 1.33(a).			
☐ An Address is being provided for the correspondence information of this application.			
Customer Number	173254		
Email Address	docketing@casimirjones.com	Add Email	Remove Email

Application Information:

Title of the Invention	FECAL SAMPLE PROCESSING AND ANALYSIS COMPRISING DETECTION OF BLOOD		
Attorney Docket Number	EXCTD-35239.313	Small Entity Status Claimed	☐
Application Type	Nonprovisional		
Subject Matter	Utility		
Total Number of Drawing Sheets (if any)		Suggested Figure for Publication (if any)	

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	EXCTD-35239.313
		Application Number	
Title of Invention	FECAL SAMPLE PROCESSING AND ANALYSIS COMPRISING DETECTION OF BLOOD		

Filing By Reference:

Only complete this section when filing an application by reference under 35 U.S.C. 111(c) and 37 CFR 1.57(a). Do not complete this section if application papers including a specification and any drawings are being filed. Any domestic benefit or foreign priority information must be provided in the appropriate section(s) below (i.e., "Domestic Benefit/National Stage Information" and "Foreign Priority Information").

For the purposes of a filing date under 37 CFR 1.53(b), the description and any drawings of the present application are replaced by this reference to the previously filed application, subject to conditions and requirements of 37 CFR 1.57(a).

Application number of the previously filed application	Filing date (YYYY-MM-DD)	Intellectual Property Authority or Country

Publication Information:

☐ Request Early Publication (Fee required at time of Request 37 CFR 1.219)
☐ Request Not to Publish. I hereby request that the attached application not be published under 35 U.S.C. 122(b) and certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication at eighteen months after filing.

Representative Information:

Representative information should be provided for all practitioners having a power of attorney in the application. Providing this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32). Either enter Customer Number or complete the Representative Name section below. If both sections are completed the customer Number will be used for the Representative Information during processing.			
Please Select One: ☒ Customer Number ☐ US Patent Practitioner ☐ Limited Recognition (37 CFR 11.9)			
Customer Number	173254		

Domestic Benefit/National Stage Information:

This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, 365(c), or 386(c) or indicate National Stage entry from a PCT application. Providing benefit claim information in the Application Data Sheet constitutes the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.

When referring to the current application, please leave the "Application Number" field blank.

Prior Application Status	Pending	Remove	
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)
	Continuation of	18539214	2023-12-13

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	EXCTD-35239.313
		Application Number	
Title of Invention	FECAL SAMPLE PROCESSING AND ANALYSIS COMPRISING DETECTION OF BLOOD		

Prior Application Status	Patented	Remove			
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)	Patent Number	Issue Date (YYYY-MM-DD)
18539214	Continuation of	15634607	2017-06-27	11845991	2023-12-19
Prior Application Status	Abandoned	Remove			
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)		
15634607	Continuation of	15010436	2016-01-29		
Prior Application Status	Abandoned	Remove			
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)		
15010436	Continuation of	13147570	2012-03-12		
Prior Application Status	Expired	Remove			
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)		
13147570	a 371 of international	PCT/GB2010/000180	2010-02-03		
Prior Application Status	Expired	Remove			
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)		
PCT/GB2010/000180	Claims benefit of provisional	61149581	2009-02-03		
Additional Domestic Benefit/National Stage Data may be generated within this form by selecting the Add button.					

Foreign Priority Information:

This section allows for the applicant to claim priority to a foreign application. Providing this information in the application data sheet constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55. When priority is claimed to a foreign application that is eligible for retrieval under the priority document exchange program (PDX)ⁱ the information will be used by the Office to automatically attempt retrieval pursuant to 37 CFR 1.55(i)(1) and (2). Under the PDX program, applicant bears the ultimate responsibility for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual property office, or a certified copy of the foreign priority application is filed, within the time period specified in 37 CFR 1.55(g)(1).

Application Number	Country ⁱ	Filing Date (YYYY-MM-DD)	Remove	Access Code ⁱ (if applicable)
Additional Foreign Priority Data may be generated within this form by selecting the Add button.				

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	EXCTD-35239.313
		Application Number	
Title of Invention	FECAL SAMPLE PROCESSING AND ANALYSIS COMPRISING DETECTION OF BLOOD		

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications

☐ This application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also contains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March 16, 2013. NOTE: By providing this statement under 37 CFR 1.55 or 1.78, this application, with a filing date on or after March 16, 2013, will be examined under the first inventor to file provisions of the AIA.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	EXCTD-35239.313
		Application Number	
Title of Invention	FECAL SAMPLE PROCESSING AND ANALYSIS COMPRISING DETECTION OF BLOOD		

Authorization or Opt-Out of Authorization to Permit Access:

When this Application Data Sheet is properly signed and filed with the application, applicant has provided written authority to permit a participating foreign intellectual property (IP) office access to the instant application-as-filed (see paragraph A in subsection 1 below) and the European Patent Office (EPO) access to any search results from the instant application (see paragraph B in subsection 1 below).

Should applicant choose not to provide an authorization identified in subsection 1 below, applicant **must opt-out** of the authorization by checking the corresponding box A or B or both in subsection 2 below.

NOTE: This section of the Application Data Sheet is **ONLY** reviewed and processed with the **INITIAL** filing of an application. After the initial filing of an application, an Application Data Sheet cannot be used to provide or rescind authorization for access by a foreign IP office(s). Instead, Form PTO/SB/39 or PTO/SB/69 must be used as appropriate.

1. Authorization to Permit Access by a Foreign Intellectual Property Office(s)

A. Priority Document Exchange (PDX) - Unless box A in subsection 2 (opt-out of authorization) is checked, the undersigned hereby **grants the USPTO authority** to provide the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the State Intellectual Property Office of the People's Republic of China (SIPO), the World Intellectual Property Organization (WIPO), and any other foreign intellectual property office participating with the USPTO in a bilateral or multilateral priority document exchange agreement in which a foreign application claiming priority to the instant patent application is filed, access to: (1) the instant patent application-as-filed and its related bibliographic data, (2) any foreign or domestic application to which priority or benefit is claimed by the instant application and its related bibliographic data, and (3) the date of filing of this Authorization. See 37 CFR 1.14(h)(1).

B. Search Results from U.S. Application to EPO - Unless box B in subsection 2 (opt-out of authorization) is checked, the undersigned hereby **grants the USPTO authority** to provide the EPO access to the bibliographic data and search results from the instant patent application when a European patent application claiming priority to the instant patent application is filed. See 37 CFR 1.14(h)(2).

The applicant is reminded that the EPO's Rule 141(1) EPC (European Patent Convention) requires applicants to submit a copy of search results from the instant application without delay in a European patent application that claims priority to the instant application.

2. Opt-Out of Authorizations to Permit Access by a Foreign Intellectual Property Office(s)

☐ A. Applicant **DOES NOT** authorize the USPTO to permit a participating foreign IP office access to the instant application-as-filed. If this box is checked, the USPTO will not be providing a participating foreign IP office with any documents and information identified in subsection 1A above.

☐ B. Applicant **DOES NOT** authorize the USPTO to transmit to the EPO any search results from the instant patent application. If this box is checked, the USPTO will not be providing the EPO with search results from the instant application.

NOTE: Once the application has published or is otherwise publicly available, the USPTO may provide access to the application in accordance with 37 CFR 1.14.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	EXCTD-35239.313
		Application Number	
Title of Invention	FECAL SAMPLE PROCESSING AND ANALYSIS COMPRISING DETECTION OF BLOOD		

Applicant Information:

Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.			
Applicant 1			
If the applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed. The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR 1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who otherwise shows sufficient proprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are also the applicant should be identified in this section.			
Clear			
☒ Assignee		☐ Legal Representative under 35 U.S.C. 117	
☐ Person to whom the inventor is obligated to assign.		☐ Person who shows sufficient proprietary interest	
If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:			
Name of the Deceased or Legally Incapacitated Inventor:			
If the Applicant is an Organization check here. ☒			
Organization Name	Exact Sciences Corporation		
Mailing Address Information For Applicant:			
Address 1	5505 Endeavor Lane		
Address 2			
City	Madison	State/Province	WI
Country	US	Postal Code	53719
Phone Number		Fax Number	
Email Address			
Additional Applicant Data may be generated within this form by selecting the Add button.			

Assignee Information including Non-Applicant Assignee Information:

Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	EXCTD-35239.313
		Application Number	
Title of Invention	FECAL SAMPLE PROCESSING AND ANALYSIS COMPRISING DETECTION OF BLOOD		

Assignee 1

Complete this section if assignee information, including non-applicant assignee information, is desired to be included on the patent application publication. An assignee-applicant identified in the "Applicant Information" section will appear on the patent application publication as an applicant. For an assignee-applicant, complete this section only if identification as an assignee is also desired on the patent application publication.

If the Assignee or Non-Applicant Assignee is an Organization check here. ☐

Prefix	Given Name	Middle Name	Family Name	Suffix

Mailing Address Information For Assignee including Non-Applicant Assignee:

Address 1			
Address 2			
City		State/Province	
Country ⁱ		Postal Code	
Phone Number		Fax Number	
Email Address			

Additional Assignee or Non-Applicant Assignee Data may be generated within this form by selecting the Add button.

Signature:

NOTE: This Application Data Sheet must be signed in accordance with 37 CFR 1.33(b). **However, if this Application Data Sheet is submitted with the INITIAL filing of the application and either box A or B is not checked in subsection 2 of the "Authorization or Opt-Out of Authorization to Permit Access" section, then this form must also be signed in accordance with 37 CFR 1.14(c).**

This Application Data Sheet **must** be signed by a patent practitioner if one or more of the applicants is a **juristic entity** (e.g., corporation or association). If the applicant is two or more joint inventors, this form must be signed by a patent practitioner, **all** joint inventors who are the applicant, or one or more joint inventor-applicants who have been given power of attorney (e.g., see USPTO Form PTO/AIA/81) on behalf of **all** joint inventor-applicants.

See 37 CFR 1.4(d) for the manner of making signatures and certifications.

Signature	/Mary Ann D. Brow/		Date (YYYY-MM-DD)	2024-10-17	
First Name	Mary Ann D.	Last Name	Brow	Registration Number	42363

Additional Signature may be generated within this form by selecting the Add button.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	EXCTD-35239.313
		Application Number	
Title of Invention	FECAL SAMPLE PROCESSING AND ANALYSIS COMPRISING DETECTION OF BLOOD		

This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

FECAL SAMPLE PROCESSING AND ANALYSIS COMPRISING DETECTION OF BLOOD

CROSS-REFERENCE TO RELATED APPLICATIONS

5 This application is a continuation of U.S. Application No. 18/539,214, filed December 13, 2023, which is a continuation of U.S. Application No. 15/634,607, filed June 27, 2017, now U.S. Patent 11,845,991, which is a continuation of U.S. Application No. 15/010,436, filed January 29, 2016, now abandoned, which is a continuation of U.S. Application No. 13/147,570, filed March 12, 2012, now abandoned, which is the U.S. national stage of
10 International Application PCT/GB2010/000180, filed February 3, 2010, which claims priority to U.S. Provisional Application No. 61/149,581, filed February 3, 2009. The contents of these applications are incorporated herein by reference in their entireties.

SEQUENCE LISTING

 The text of the computer readable sequence listing filed herewith, titled “35239-
15 313_SEQUENCE_LISTING”, created October 15, 2024, having a file size of 35,641 bytes, is hereby incorporated by reference in its entirety.

FIELD OF THE INVENTION

 The present invention relates to methods and kits for analysis of fecal samples comprising removing a portion of a collected fecal sample and adding the removed portion of
20 the fecal sample to a buffer that prevents denaturation or degradation of blood proteins found in the sample, and comprising detection of blood in the removed portion of the fecal sample, *e.g.*, by immunoassay.

BACKGROUND OF THE INVENTION

 Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide, and is
25 the second leading cause of cancer-related deaths in the United States. A patient's prognosis is good if the cancer is caught early, when the site of the cancer is confined to its site of origin. However, the cure rates fall once the cancer has spread. Most colon cancers arise from conventional adenomatous polyps (conventional adenoma-to-carcinoma sequence), while some colon cancers appear to arise from the recently recognized serrated adenomatous polyp

(serrated adenoma-to-carcinoma theory). Because conventional adenomas and serrated adenomas are usually asymptomatic, mass screening of asymptomatic patients has become the cornerstone for detecting and eliminating these precursor lesions to reduce the risk of colon cancer.

5 A number of different screening methods for CRC are available. Procedures such as digital rectal examination (DRE); colonoscopy or sigmoidoscopy are highly invasive, painful and can cause a great deal of patient discomfort. Other less invasive screening tests include fecal occult blood test (FOBT); fecal immunochemical test (FIT); barium enema with air contrast; virtual colonoscopy; biopsy (e.g., CT guided needle biopsy); and imaging
10 techniques (e.g., ultrasound, CT scan, PET scan, and MRI).

Colonoscopy has become the primary screening test for CRC because of its high sensitivity and specificity, and the ability to perform polypectomy. While sensitive and specific, the procedure is invasive, costly, has limited availability and includes certain risks such as induction of infection and perforation of the bowel.

15 A commonly used and less expensive way of screening for CRC is a fecal occult blood test (FOBT), which tests for the presence of blood in faeces. The presence of haemoglobin as a representative blood protein in faeces is an indicator of intestinal bleeding, which is frequently associated with CRC. However, since occult in a fecal sample could be indicative of a variety of gastrointestinal disorders, further medical testing such as
20 colonoscopy remains necessary to identify colorectal cancer.

Fecal occult blood tests fall primarily into two categories, tests based on the use of chromogenic chemical reagents such as gum guaiac and immunochemical tests. The chemically based guaiac methods determine the presence of occult blood by the detection of the peroxidase activity of the hemoglobin in the blood present in the faecal sample. They
25 require catalysis of peroxide into oxygen and water, and the subsequent oxidation of a colorless dye (most often into a colored form). However, peroxidase activity is also found in meats and vegetables. In order to produce accurate results, these tests require restriction of the intake of certain foods, drugs, vitamins, and other substances prior to and during the sample collection period. The sensitivity of the most commonly used guaiac FOBT
30 (Hemoccult) is approximately 50%. Despite a specificity of 98%, the positive predictive value for FOBT is low. Methods of detecting occult blood based on porphyrin (heme and

protoporphyrin IX) analysis or immunologic tests using anti-hemoglobin antibodies improve on these results. Immunochemical tests (FIT or iFOBT) that use anti-hemoglobin antibodies specific for human blood in extracts from stool do not require dietary restrictions; however, they are more complicated and more expensive than peroxidase-based tests. In addition, human hemoglobin in fecal samples degrades with time, resulting in a loss of antigenicity which can produce false negative results. Reported sensitivity of these immunologic tests varies widely but is typically 60-80% depending on the population tested. Specificity is estimated to be ~98%. Because of the intermittent nature of colorectal bleeding, the sensitivity of FOBT and FIT is directly proportional to the number of samples taken and the frequency of testing.

Recent developments in testing look specifically for mutations in DNA characteristic of colorectal neoplasia that are detectable in exfoliated epithelial cells in the stool (Pignone, et al., 2002; Ahlquist, et al., 2002). While neoplastic bleeding is intermittent, epithelial shedding is continual, potentially making stool-based DNA testing (i.e., also known as fecal DNA [f-DNA] and stool DNA [sDNA]) testing more sensitive than other methods. Early studies of molecular fecal screening primarily focused on single mutations. Gene mutations in P53, K-ras, and BAT 26, for instance, have been linked to colorectal cancer and remain detectable in fecal samples. Colorectal neoplasms are varied in nature and no single mutation has been identified as being expressed universally. For this reason, multiple target assay panels (MTAP) are preferably used. PreGen-Plus™ (EXACT Sciences Corporation, Maynard, MA; Laboratory Corporation of America, Burlington, NC) is a single test that identifies the presence of 23 different microsatellite (MSI) mutations known to be associated with CRC, including mutations in BAT-26. Additionally, 21 other point mutations in other genes associated with CRC are included in this test: APC, K-ras, and p53. This test is further designed to detect long DNA fragments, which have been specifically associated with cells called non-apoptotic colonocytes, which are common in CRC. While this test is more sensitive than fecal occult blood testing, it is not as sensitive as colonoscopy and will miss about half of cancers in an average risk group of people without symptoms.

Increased DNA methylation is an epigenetic alteration that is common in human cancers and is often associated with transcriptional silencing. Aberrantly methylated DNA has also been proposed as a potential tumor marker for CRC detection. Genes such as vimentin, which are transcriptionally silent in normal epithelium, have been considered as

targets for cancer-associated aberrant methylation and for use as cancer markers (JNCI Journal of the National Cancer Institute 2005 97(15):1124-1132). A combined assay utilizing hypermethylated vimentin gene (hV) and a two site DNA integrity assay (DY), demonstrated a sensitivity of 88% for CRC with a specificity of 82% (Am J Gastroenterol. 2008 Nov; 103(11):2862-70). Further, ColoSure® is a single marker laboratory developed, stool based DNA test. This method examines DNA in exfoliated colon cells for cancer-associated aberrant methylation of the vimentin gene and reaches a sensitivity range of 72-77% and a specificity range of 83-94% in average risk individuals.

Protein tests provide an alternative method for detecting CRC. Tests assessing the presence of tumor-derived enzymes such as M2 pyruvate kinase (M2-PK), and/or proteins such as calprotectin, carcinoembryonic antigen (CEA), tissue inhibitor of metalloproteinase-1 (TIMP-1) and S100 calcium binding protein A12 (S100A12) have been described. A diagnosis of colorectal cancer using a combination of fecal occult blood and novel fecal protein markers S100A12 and TIMP-1 has been described in Clin Gastroenterol Hepatol. 2008 Oct;6(10):1122-8. Dimeric isoenzyme of pyruvate kinase, M2-PK, expressed by tumor cells, has as well been proposed as a screening tool for CRC. The performance of fecal M2-PK has been evaluated with IFOBT and colonoscopy in Am J Gastroenterol. 2008 Jun;103(6):1496-504. Compared to immunochemical FOBTs, TuM2-PK does not have supplemental value for screening for CRC because of a lower sensitivity and specificity (Eur J Gastroenterol Hepatol. 2007 Oct;19(10):878-82)

Although combined assays for detecting CRC have been described, their approach targets either multiple protein markers or either multiple DNA alterations. To date, immunochemical tests and DNA tests for CRC detection have been evaluated and compared on a separate basis only.

EP0308227 describes a chemical fecal occult blood test employing a guaiac matrix.

EP0032782 describes a method for the detection of haemoglobin or decomposition products of haemoglobin in feces by means of an immunological reaction by using an antibody specific for human haemoglobin.

US7288413 describes methods that combine a chemical fecal occult blood test and an immunochemical fecal occult blood test.

WO 04/092709 concerns a fecal blood test involving the dispersement of a dye in toilet water.

EP0817968 describes several suitable stool collecting and testing methods and devices.

- 5 WO 05/017207 discloses that the vimentin gene can be a common target for methylation and epigenetic gene silencing in colon neoplasia, and may function as a candidate tumor suppressor gene.

WO 2008/084219 relates to detection of colorectal cancer based upon determining methylation of a number of different genes, including panels of genes.

- 10 WO 2006/113671 and WO 2008/010975 describe methylation markers relevant to colorectal cancer.

SUMMARY OF THE INVENTION

The invention provides a method of detecting a predisposition to, or the incidence of, colorectal cancer in a faecal sample comprising:

- 15 (a) detecting the presence of blood in the faecal sample, wherein detection of the presence of blood is indicative of a predisposition to, or the incidence of, colorectal cancer,

(b) detecting an epigenetic modification in the DNA contained within the faecal sample, wherein detection of the epigenetic modification is indicative of a predisposition to, or the incidence of, colorectal cancer

- 20 and based upon a positive result obtained in either (a) or (b) or in both (a) and (b) detecting a predisposition to, or the incidence of, colorectal cancer.

- Also described herein is a method of sample processing, prior to carrying out a method of the invention, comprising removing a portion of a collected faecal sample and adding the removed portion of the sample to a buffer which prevents denaturation or
25 degradation of blood proteins found in the sample.

The invention also provides a method of detecting a predisposition to, or the incidence of, colorectal cancer in a sample comprising detecting an epigenetic modification in a panel of at least two genes selected from PHACTR3, NDRG4 and FOXE1 , wherein detection of the epigenetic modification in at least one of the genes in the panel is indicative of a predisposition to, or the incidence of, colorectal cancer.

The invention also provides a method of detecting a predisposition to, or the incidence of, cancer (and in particular colorectal cancer) in a sample comprising detecting an epigenetic modification in at least one gene selected from LAMA1 and CDO1, wherein detection of the epigenetic modification in the at least one gene is indicative of a predisposition to, or the incidence of, cancer (and in particular colorectal cancer).

The invention also relates to a method of detecting a predisposition to, or the incidence of, colorectal cancer (in particular in a faecal sample) comprising detecting an epigenetic modification in at least one gene selected from GPNMB and MMP2, wherein detection of the epigenetic modification in the at least one gene is indicative of a predisposition to, or the incidence of, colorectal cancer.

In related aspects, the invention provides

a method for predicting the likelihood of successful treatment of colorectal cancer with a DNA demethylating agent and/or a DNA methyltransferase inhibitor and/or HDAC inhibitor comprising detecting an epigenetic modification in:

- (a) a panel of at least two genes selected from PHACTR3, NDRG4 and FOXE1,
- (b) at least one gene selected from LAMA1 and CDO1; or
- (c) at least one gene selected from GPNMB and MMP2 (in a faecal sample) wherein detection of the epigenetic modification in at least one of the genes in the panel or in the at least one gene is indicative that the likelihood of successful treatment is higher than if the epigenetic modification is not detected.

a method for predicting the likelihood of resistance to treatment of colorectal cancer with a DNA demethylating agent and/or DNA methyltransferase inhibitor and/or HDAC inhibitor comprising detecting an epigenetic modification in

- (a) a panel of at least two genes selected from PHACTR3, NDRG4 and FOXE1 ,
- (b) at least one gene selected from LAMA1 and CDO1; or
- (c) at least one gene selected from GPNMB and MMP2 (in a faecal sample) wherein detection of the epigenetic modification in at least one of the genes in the panel or in the at least one gene is indicative that the likelihood of resistance to treatment is lower than if the epigenetic modification is not detected.

a method of selecting a suitable treatment regimen for colorectal cancer comprising detecting an epigenetic modification in

- (a) a panel of at least two genes selected from PHACTR3, NDRG4 and FOXE1 ,
- (b) at least one gene selected from LAMA1 and CDO1; or
- (c) at least one gene selected from GPNMB and MMP2 (in a faecal sample) wherein detection of the epigenetic modification in at least one of the genes in the panel or in the at least one gene results in selection of a DNA demethylating agent and/or a DNA methyltransferase inhibitor and/or a HDAC inhibitor for treatment and wherein if the epigenetic modification is not detected, a DNA demethylating agent and/or a DNA methyltransferase inhibitor and/or a HDAC inhibitor is not selected for treatment.

a method for monitoring treatment of colorectal cancer with a DNA demethylating agent and/or a DNA methyltransferase inhibitor and/or HDAC inhibitor comprising detecting an epigenetic modification in

- (a) a panel of at least two genes selected from PHACTR3, NDRG4 and FOXE 1 ,
- (b) at least one gene selected from LAMA1 and CDO1 ; or
- (c) at least one gene selected from GPNMB and MMP2 (in a faecal sample) wherein detection of a reduction in the epigenetic modification in at least one of the genes in the panel or in the at least one gene as treatment progresses is indicative of successful treatment.

- Thus, the epigenetic modification may be measured at the start of the treatment and then once or more following treatment, or as treatment progresses, in order to determine if the

treatment is achieving the desired effect. A return to lower levels of methylation of the genes is considered indicative of effective treatment.

The invention also relates to a kit for detecting a predisposition to, or the incidence of, colorectal cancer in a faecal sample comprising:

5 (a) means for detecting an epigenetic modification in the DNA contained within the faecal sample, wherein detection of the epigenetic modification is indicative of a predisposition to, or the incidence of, colorectal cancer, and

(b) means for detecting the presence of blood in the faecal sample, wherein detection of the presence of blood is indicative of a predisposition to, or the incidence of, colorectal
10 cancer.

Also provided is a kit for any of:

(a) detecting a predisposition to, or the incidence of, colorectal cancer in a sample

(b) monitoring treatment of colorectal cancer with a DNA demethylating agent and/or a DNA methyltransferase inhibitor and/or HDAC inhibitor

15 (c) predicting the likelihood of successful treatment of colorectal cancer with a DNA demethylating agent and/or a DNA methyltransferase inhibitor and/or HDAC inhibitor

(d) predicting the likelihood of resistance to treatment of colorectal cancer with a DNA demethylating agent and/or DNA methyltransferase inhibitor and/or HDAC inhibitor;
or

20 (e) selecting a suitable treatment regimen for colorectal cancer comprising means for detecting an epigenetic modification in a panel of at least two genes selected from PHACTR3, NDRG4 and FOXE1.

Similarly, the invention also provides a kit for any of:

(a) detecting a predisposition to, or the incidence of, colorectal cancer in a sample

(b) predicting the likelihood of successful treatment of colorectal cancer with a DNA demethylating agent and/or a DNA methyltransferase inhibitor and/or HDAC inhibitor

(c) predicting the likelihood of resistance to treatment of colorectal cancer with a DNA demethylating agent and/or DNA methyltransferase inhibitor and/or HDAC inhibitor;

5 or

(d) selecting a suitable treatment regimen for colorectal cancer comprising means for detecting an epigenetic modification in at least one gene selected from LAM A1 and CD01.

The invention also provides a kit for any of:

(a) detecting a predisposition to, or the incidence of, colorectal cancer in a sample

10 (b) predicting the likelihood of successful treatment of colorectal cancer with a DNA demethylating agent and/or a DNA methyltransferase inhibitor and/or HDAC inhibitor

(c) predicting the likelihood of resistance to treatment of colorectal cancer with a DNA demethylating agent and/or DNA methyltransferase inhibitor and/or HDAC inhibitor;

15 or (d) selecting a suitable treatment regimen for colorectal cancer comprising means for detecting an epigenetic modification in at least one gene selected from GPNMB and MMP2 and means for processing a faecal sample.

20 The invention also provides a method of detecting a predisposition to, or the incidence of, colorectal cancer in a faecal sample comprising detecting an epigenetic modification in the DNA contained within the faecal sample, wherein detection of the epigenetic modification is indicative of a predisposition to, or the incidence of, colorectal cancer, characterised in that the faecal sample has previously been stored for at least approximately 6 months, 1, 2, 3, 4, 5, 6 or more years and/or is less than approximately 4, 3, 2, or 1g in weight.

DETAILED DESCRIPTION OF THE INVENTION

25 The invention, as set out in the claims, is based upon successful attempts to improve the detection of colorectal cancer. In particular, the invention aims to improve the positive and negative predictive value and also the sensitivity and specificity of detection of colorectal

cancer through non-invasive means. The methods of the invention may permit effective detection of colorectal cancer without the requirement for relatively expensive, highly invasive and painful procedures such as digital rectal examination, colonoscopy and sigmoidoscopy to be performed. The invention is based upon a combination of tests for
5 detecting proteins and epigenetic modification markers respectively in the same faecal sample, shown for the first time herein to provide a particularly useful overall test.

Thus, according to a first aspect, the invention provides a method of detecting a predisposition to, or the incidence of, colorectal cancer in a faecal sample comprising, consisting essentially of or consisting of:

10 (a) detecting the presence of blood in the faecal sample, wherein detection of the presence of blood is indicative of a predisposition to, or the incidence of, colorectal cancer,

(b) detecting an epigenetic modification in the DNA contained within the faecal sample, wherein detection of the epigenetic modification is indicative of a predisposition to, or the incidence of, colorectal cancer

15 and based upon a positive result obtained in either (a) or (b) or in both (a) and (b) detecting a predisposition to, or the incidence of, colorectal cancer.

As shown herein, the combination of methylation marker assay and fecal occult blood test (FOBT) gives very specific and sensitive results.

20 The combined methods of the invention improve the negative predictive value of the existing single tests. By improving sensitivity, the number of false negative results is decreased and this improves negative predictive value.

Step (a) of the methods involves detecting the presence of blood in the faecal sample, wherein detection of the presence of blood is indicative of a predisposition to, or the incidence of, colorectal cancer. Blood in the faeces is an indicator of intestinal bleeding,
25 which is frequently associated with colorectal cancer. Thus, detection of blood in the faecal sample is considered a "positive" result in step (a). Any suitable method for detecting the presence of blood in the sample may be employed. Often, the methods of detecting blood will rely upon detecting a representative blood protein in the faecal sample. In certain embodiments, detecting the presence of blood in the faecal sample comprises, consists

essentially of or consists of detection of haemoglobin in the faecal sample. Detection may be through any suitable means, and includes all variants of fecal occult blood tests. The test may be chromogenic or immunological in certain embodiments. The test may rely upon peroxidase activity of hemoglobin. Chromogenic tests are well known and commercially available and may rely upon chemical reagents such as gum guaiac. In specific embodiments, haemoglobin in the faecal sample is detected through immunochemical means. This may involve anti-hemoglobin antibodies in certain embodiments. The term "antibody" or "antibodies" herein refers to an antibody or antibodies, or a derivative thereof that retains specific binding activity. By specific binding activity is meant the ability to specifically bind to hemoglobin. Thus, such a reagent does not bind, or does not bind to a significant degree, to unrelated proteins found in the faecal sample. Any antibody or derivative may be employed. Thus, the antibody may be a monoclonal or polyclonal antibody. The derivative of the antibody that retains specific binding activity may comprise, consist essentially of or consist of a humanized version of a non-human antibody, a heavy chain antibody, a single domain antibody, a nanobody, a Fab fragment or scFv etc. in certain embodiments. Numerous techniques are available for producing antibodies and their derivatized forms, as would be well known to one skilled in the art.

As mentioned above, the combination of techniques maximises sensitivity of detection, without significantly compromising specificity. Thus, the threshold detection concentrations for detection of blood/hemoglobin in step (a) may be those typically employed in fecal occult blood tests. Adding in the step (b) test improves overall sensitivity by picking up additional positive samples. For example, in some embodiments, the result in step (a) is considered positive if the concentration of hemoglobin detected is more than between (about) 50 to (about) 150 ng/ml. In more specific embodiments, the result in step (a) is considered positive if the concentration of hemoglobin detected is more than (about) 100 ng/ml.

However, in other embodiments, the methods of the invention may be employed to improve the sensitivity of the step (a) method, whilst preventing a resultant loss in specificity. By lowering the threshold concentration of blood to be detected in the faecal sample to give a positive result in step (a), the sensitivity of the step (a) method is increased. In order to retain specificity, the step (b) method is employed on those samples in which low levels, that is to say lower than the typically used threshold, of blood were detected in step (a). A positive result from the step (b) method is required to confirm the positive result in step (a) for the

"low level" samples. For those samples having blood (especially hemoglobin) concentrations above the typically employed threshold in step (a), it is not necessary to perform the method of step (b), since for these samples the step (a) method is sufficiently specific for this not to be necessary. This has the advantage that the step (b) test is not required for all samples, thus
5 reducing costs and increasing throughput. Thus, in certain embodiments, the result in step (a) is considered positive if the concentration of hemoglobin detected is lower than is typically employed as the threshold concentration of hemoglobin in hemoglobin detection tests, but for those samples in which a "lower than typical threshold" concentration of hemoglobin is detected, step (b) is performed on these samples. The detection of the epigenetic modification
10 in step (b) is then used to confirm the positive result in step (a). The step (b) test is not employed for those samples in which the concentration of hemoglobin detected is higher than the threshold typically employed in hemoglobin detection tests.

In specific embodiments, the result in step (a) is considered positive if the concentration of hemoglobin detected is more than or at least (about) 5 to (about) 50 ng/ml,
15 more specifically more than or at least (about) 5 to (about) 20 ng/ml and more particularly more than or at least (about) 10 ng/ml. By lowering the threshold, the sensitivity of the test is increased. In such embodiments, step (b) is performed only in the event that the concentration of hemoglobin detected is between (about) 5 ng/ml and (about) 250 ng/ml, more specifically between (about) 10 ng/ml and (about) 200 ng/ml. The detection of the epigenetic
20 modification in step (b) is then used to confirm the positive result in step (a). Thus, a positive result in step (b) confirms the result in step (a) as positive. If no epigenetic modification of the DNA is detected, the result of step (a) is considered negative. For samples in which the concentration of hemoglobin detected is more than or at least (about) 200 ng/ml (or (about) 250 ng/ml), it is not necessary to perform step (b), since the result in step (a) will be of high
25 specificity (i.e. is unlikely to be a false positive).

Step (b) involves detecting an epigenetic modification in the DNA contained within the faecal sample, wherein detection of the epigenetic modification is indicative of a predisposition to, or the incidence of, colorectal cancer. Thus, detection of the epigenetic modification is considered a "positive" result in step (b).

30 In some embodiments, the epigenetic modification is detected in at least one gene selected from PHACTR3, NDRG4, FOXE1, GATA4, GPNMB, TFPI2, SOX17, SYNE1, LAMA1, MMP2, OSMR, SFRP2 and CDO1, with detection of the epigenetic modification

in at least one of the genes providing an indication of a predisposition to, or incidence of, colorectal cancer.

In certain embodiments, the epigenetic modification is detected in at least one gene selected from PHACTR3, NDRG4 and FOXE1, with detection of the epigenetic
5 modification in at least one of the genes providing an indication of a predisposition to, or incidence of, colorectal cancer.

PHACTR3 is the gene symbol approved by the HUGO Gene Nomenclature Committee. The gene is located on chromosome 20 (location 20q13.32-q13.33) and the gene sequence is listed under the accession numbers AJ311122 and NM_080672. The gene
10 encodes the phosphatase and actin regulator 3.

NDRG4 is the gene symbol approved by the HUGO Gene Nomenclature Committee. The gene is located on chromosome 16 (location q21-q22.3) and the gene sequence is listed under the accession number AB044947. The gene encodes NDRG family member 4.

FOXE1 is the gene symbol approved by the HUGO Gene Nomenclature Committee.
15 The gene is located on chromosome 9 (location 9q22) and the gene sequence is listed under the accession number U89995. The gene encodes the forkhead box E1 (thyroid transcription factor 2).

GATA4 is the gene symbol approved by the HUGO Gene Nomenclature Committee. The gene is located on chromosome 8 (location 8p23.1-p22) and the gene sequence is listed
20 under the accession numbers AK097060 and NMJ302052. The gene encodes the GATA binding protein 4.

GPNUMB is the gene symbol approved by the HUGO Gene Nomenclature Committee. The gene is located on chromosome 7 (location 7p) and the gene sequence is listed under the accession numbers X76534 and NMJ301005340. The gene encodes the glycoprotein
25 (transmembrane) nmb.

TFPI2 is the gene symbol approved by the HUGO Gene Nomenclature Committee. The gene is located on chromosome 7 (location 7q) and the gene sequence is listed under the accession numbers L27624 and NM_006528. The gene encodes tissue factor pathway inhibitor 2.

SOX17 is the gene symbol approved by the HUGO Gene Nomenclature Committee. The gene is located on chromosome 8 (location 8q11.23) and the gene sequence is listed under the accession number AB073988. The gene encodes SRY (sex determining region Y)-box 17.

- 5 SYNE1 is the gene symbol approved by the HUGO Gene Nomenclature Committee. The gene is located on chromosome 6 (location 6q24.2-q25.3) and the gene sequence is listed under the accession number AB018339. The gene encodes spectrin repeat containing, nuclear envelope 1.

- 10 LAMA1 is the gene symbol approved by the HUGO Gene Nomenclature Committee. The gene is located on chromosome 18 (location 18p11.3) and the gene sequence is listed under the accession numbers X58531 and NM_005559. The gene encodes laminin, alpha 1.

- 15 MMP2 is the gene symbol approved by the HUGO Gene Nomenclature Committee. The gene is located on chromosome 16 (location 16q13-q21) and the gene sequence is listed under the accession number NM_001127891. The gene encodes matrix metalloproteinase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase).

OSMR is the gene symbol approved by the HUGO Gene Nomenclature Committee. The gene is located on chromosome 5 (location 5p13.2) and the gene sequence is listed under the accession number U60805 and NM_003999. The gene encodes the oncostatin M receptor.

- 20 SFRP2 is the gene symbol approved by the HUGO Gene Nomenclature Committee. The gene is located on chromosome 4 (location 4q31.3) and the gene sequence is listed under the accession number AF017986. The gene encodes the secreted frizzled-related protein 2.

CDO1 is the gene symbol approved by the HUGO Gene Nomenclature Committee. The gene is located on chromosome 5 (location 5q23.2) and the gene sequence is listed under the accession number NM_001801. The gene encodes the cysteine dioxygenase, type I.

- 25 By "gene" is meant the specific known gene in question. It may also relate to any gene which is taken from the family to which the named "gene" belongs, in certain circumstances, and includes according to all aspects of the invention not only the particular sequences found in the publicly available database entries, but also encompasses transcript and nucleotide variants of these sequences, with the proviso that methylation or another

epigenetic modification of the gene is linked to the incidence of colorectal cancer. Variant sequences may have at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% nucleotide sequence identity with the nucleotide sequences in the database entries. Computer programs for
5 determining percentage nucleotide sequence identity are available in the art, including the Basic Local Alignment Search Tool (BLAST) available from the National Center for Biotechnology Information.

The methods of the invention are generally in vitro methods carried out on an isolated test sample. The methods are used to diagnose colorectal cancer. In certain embodiments the
10 methods may also include the step of obtaining the sample. The test sample is generally from a human subject. The subject may be suspected of being tumorigenic. More specifically the subject may be suspected of suffering from a colorectal cancer.

In specific embodiments of the methods, the epigenetic modification is detected in a panel of at least two genes selected from PHACTR3, NDRG4 and FOXE1 , with detection of
15 the epigenetic modification in at least one of the genes providing an indication of a predisposition to, or incidence of, colorectal cancer. Specific panels which may be employed comprise, consist essentially of or consist of PHACTR3, NDRG4 and FOXE1, NDRG4 and FOXE1 , PHACTR3 and NDRG4, or PHACTR3 and FOXE1.

In other embodiments, the epigenetic modification is detected in at least one gene
20 selected from LAMA1 and CDO1. In further embodiments, the epigenetic modification is detected in at least one gene selected from GPNMB and MMP2. The methods of the invention may have diagnostic and prognostic value, and this is included within the definition of the term "detecting a predisposition to, or the incidence of, colorectal cancer". The prognostic value of the methods of the invention may be used as a marker of potential susceptibility to
25 colorectal cancer or as a marker for progression from adenoma to cancer for example. Thus patients at risk may be identified before the disease has a chance to manifest itself in terms of symptoms identifiable in the patient. Initial detection as well as follow-up detection, for example following treatment, is also included within the definition. Follow up detection may be performed after any treatment. Examples include following polypectomy (removal of
30 polyps) and following surgery to remove a colorectal carcinoma, severe neoplasia or advanced adenoma.

The methods of the invention may be carried out on purified or unpurified DNA-containing samples. However, in specific embodiments, DNA is isolated/extracted/purified from the sample. Any suitable DNA isolation technique may be utilised. Examples of purification techniques may be found in standard texts such as Molecular Cloning - A Laboratory Manual (Third Edition), Sambrook and Russell (see in particular Appendix 8 and Chapter 5 therein). In some embodiments, purification involves alcohol precipitation of DNA. Preferred alcohols include ethanol and isopropanol. Suitable purification techniques also include salt-based precipitation methods. Thus, in specific embodiments the DNA purification technique comprises use of a high concentration of salt to precipitate contaminants. The salt may comprise, consist essentially of or consist of potassium acetate and/or ammonium acetate for example. The method may further include steps of removal of contaminants which have been precipitated, followed by recovery of DNA through alcohol precipitation.

In alternative embodiments, the DNA purification technique is based upon use of organic solvents to extract contaminants from cell lysates. Thus, in certain embodiments, the method comprises use of phenol, chloroform and isoamyl alcohol to extract the DNA. Suitable conditions are employed to ensure that the contaminants are separated into the organic phase and that DNA remains in the aqueous phase.

In specific embodiments of these purification techniques, extracted DNA is recovered through alcohol precipitation, such as ethanol or isopropanol precipitation.

Amplification of DNA (using PCR) from natural sources is often inhibited by co-purified contaminants and various methods adopted for DNA extraction from environmental samples are available and provide an alternative for isolating DNA from faecal samples, according to specific embodiments of the invention. For instance, the QIAamp DNA Stool Mini Kit from QIAGEN adsorbs DNA-damaging substances and PCR inhibitors present in the sample by InhibitEX. Other examples for application to faecal samples include the Wizard Genomic DNA Purification Kit (Promega), the NucliSENS® easyMAG™ (Biomérieux) and nucleic acid purification kits manufactured by Macherey Nagel.

The methods of the invention may also, as appropriate, incorporate quantification of isolated/extracted/purified DNA in the sample. Quantification of the DNA in the sample may be achieved using any suitable means. Quantitation of nucleic acids may, for example, be

based upon use of a spectrophotometer, a fluorometer or a UV transilluminator. Examples of suitable techniques are described in standard texts such as Molecular Cloning - A Laboratory Manual (Third Edition), Sambrook and Russell (see in particular Appendix 8 therein). In some embodiments, kits such as the Picogreen® dsDNA quantitation kit available from
5 Molecular Probes, Invitrogen may be employed to quantify the DNA.

The inventor has determined that faecal samples for use in the invention do not necessarily have to be freshly collected. This applies in particular for performing step (b) and thus also the further methods of the invention discussed herein where epigenetic modifications in specific genes are determined in faecal samples. Thus, samples collected 1,
10 2, 3, 4, 5, 6 or more years ago may be employed. The historical samples may have been frozen for storage. Freezing is performed at a suitable temperature, such as 20°C for example. Lyophilisation may be performed in certain embodiments to permit storage of the faecal samples. The sample may be frozen without the addition of a stabilizing buffer in certain
15 embodiments as it has been shown that this is not necessary, when the sample is frozen, in order to retain DNA integrity in the sample. In other embodiments, a suitable stabilizing buffer as known to those in the art, may be added to the sample before and/or after storage.

The inventor has also discovered that a minimal stool sample, including a minimal sample derived from a historical sample as discussed herein, may successfully be employed in the methods of the invention. This is particularly applicable to performing step (b) and thus
20 is also applicable to the further aspects of the invention discussed herein where epigenetic modifications in specific genes are determined, in faecal samples. Thus, only a portion of a collected faecal sample need be employed in the methods of the invention in order to achieve reliable results. Reliable results may be achieved by isolating, extracting or purifying DNA from less than 5g of faecal sample, in particular from approximately 4, 3, 2, or 1g of faecal
25 sample. The faecal sample may be present in an appropriate volume of homogenizing buffer to facilitate DNA isolation, extraction and purification.

As discussed above, suitable commercially available kits, such as the QIAamp DNA Stool Mini Kit, may be employed in order to extract the DNA and remove potential inhibitors found in the faecal sample. This may involve processing smaller volumes of the overall
30 faecal sample and pooling the resultant DNA in certain embodiments. For example, volumes of approximately 1ml or less, such as approximately 750, 500, 250 or 100 µl may be used for DNA extraction. The resultant DNA from 2, 3, 4, 5 or more extractions may be pooled to

give an overall DNA sample to be assessed according to the methods of the invention. DNA in the sample, pre- and/or post-pooling can be quantified as required, as discussed herein.

Thus, the invention provides a method of detecting a predisposition to, or the incidence of, colorectal cancer in a faecal sample comprising, consisting essentially of or consisting of detecting an epigenetic modification in the DNA contained within the faecal sample, wherein detection of the epigenetic modification is indicative of a predisposition to, or the incidence of, colorectal cancer, characterised in that the faecal sample has previously been stored for at least approximately 6 months, 1, 2, 3, 4, 5, 6 or more years and/or is less than approximately 4, 3, 2, or 1g in weight (prior to addition of homogenization buffer).

The detailed discussion of determination of epigenetic modifications provided herein applies mutatis mutandis to this aspect of the invention.

"Colorectal cancer", also called colon cancer or bowel cancer, is defined to include cancerous growths, carcinomas, severe neoplasias and advanced adenomas in the colon, rectum and appendix.

"Epigenetic modification" is defined herein to include any alteration in the DNA, generally resulting in diminished gene expression, which is mediated by mechanisms other than alterations in the primary nucleotide sequence of a gene. Epigenetic modifications may, in certain circumstances be stable heritable traits. A number of related mechanisms that cause alteration in gene expression are recognised and include DNA methylation, histone changes (for example changes in histone acetylation) which may lead to chromatin remodelling and RNA interference. In many cases, hypermethylation of DNA incorrectly switches off critical genes allowing cancers to develop and progress. In specific embodiments, the epigenetic modification is methylation. In particular, aberrant methylation, which may be referred to as hypermethylation, of the gene or genes is detected. Typically, the methylation status is determined in suitable CpG islands which are often found in the promoter region of the gene(s). The term "methylation", "methylation state" or "methylation status" refers to the presence or absence of 5-methylcytosine at one or a plurality of CpG dinucleotides within a DNA sequence. CpG dinucleotides are typically concentrated in the promoter regions and exons of human genes. CpG dinucleotides susceptible to methylation may be found in the promoter region, exons and introns of human genes. Promoter, exon and intron regions can all thus be assessed for methylation. A "promoter" is a region extending typically between

approximately 1 Kb, 500 bp or 150 to 300 bp upstream from the transcription start site. In some embodiments, the CpG island surrounding or positioned around the transcription start site is analysed to determine its methylation status. Alternatively, the methylation status of the exon and/or intron regions of may be determined as appropriate. The identification of
5 CpG islands, to assess for determination of methylation status, is a matter of routine for one skilled in the art and various techniques, including in silico techniques, are available.

Since hypermethylation of a gene may result in diminished gene expression it may be possible, in certain embodiments, to carry out the methods of the invention by determining gene expression of the DNA in the faecal sample, rather than investigating the methylation
10 status of the DNA directly. Many suitable techniques are available for determining gene expression at either the RNA or protein level. In certain embodiments, expression at the RNA level is determined by reverse transcriptase polymerase chain reaction (RT-PCR). In alternative embodiments, expression is determined at the protein level. Again, any suitable technique may be employed such as western blotting, ELISA etc.

15 Measurement of expression of a gene on its own may not necessarily conclusively indicate that the silencing is epigenetic, as the mechanism of silencing could be genetic, for example, by somatic mutation. Accordingly, in certain embodiments, the methods of the invention incorporate an appropriate re-expression assay which is designed to reverse epigenetic silencing. Appropriate treatment of the sample using a demethylating agent, such
20 as a DNA-methyltransferase (DMT) inhibitor may reverse epigenetic silencing of the relevant gene. Suitable reagents include, but are not limited to, DAC (5'-deazacytidine), TSA or any other treatment affecting epigenetic mechanisms present in cell lines. Suitable reagents are discussed herein with respect to the pharmacogenetic, treatment monitoring and treatment aspects of invention, which discussion applies mutatis mutandis. Typically, expression is
25 reactivated or reversed upon treatment with such reagents, indicating that the silencing is epigenetic.

Determination of the methylation status may be achieved through any suitable means. Suitable examples include bisulphite genomic sequencing and/or by methylation specific PCR. Various techniques for assessing methylation status are known in the art and can be
30 used in conjunction with the present invention: sequencing, methylation-specific PCR (MS-PCR), melting curve methylation-specific PCR (McMS-PCR), MLPA with or without bisulphite treatment, QAMA (Zeschnigk et al, 2004), MSRE-PCR (Melnikov et al, 2005),

MethyLight (Eads et al., 2000), ConLight-MSP (Rand et al., 2002), bisulphite conversion-specific methylation-specific PCR (BS-MSP)(Sasaki et al., 2003), COBRA (which relies upon use of restriction enzymes to reveal methylation dependent sequence differences in PCR products of sodium bisulphite - treated DNA), methylation-sensitive single-nucleotide primer
5 extension conformation(MS-SNuPE), methylation- sensitive single-strand conformation analysis (MS-SSCA), Melting curve combined bisulphite restriction analysis (McCOBRA)(Akey et al., 2002), PyroMethA, HeavyMethyl (Cottrell et al. 2004), MALDI-TOF, MassARRAY, Quantitative analysis of methylated alleles (QAMA), enzymatic regional methylation assay (ERMA)1 QBSUPT, MethylQuant, Quantitative PCR sequencing and
10 oligonucleotide-based microarray systems, Pyrosequencing, Meth-DOP-PCR. A review of some useful techniques for DNA methylation analysis is provided in Nucleic acids research, 1998, Vol. 26, No. 10, 2255-2264, Nature Reviews, 2003, Vol.3, 253-266; Oral Oncology, 2006, Vol. 42, 5-13, which references are incorporated herein in their entirety.

Techniques for assessing methylation status are based on distinct approaches. Some
15 include use of endonucleases. Such endonucleases may either preferentially cleave methylated recognition sites relative to non-methylated recognition sites or preferentially cleave non-methylated relative to methylated recognition sites. Some examples of the former are Ace III, Ban I, BstN I, Msp I, and Xma I. Examples of the latter are Ace II, Ava I, BssH II, BstU I, Hpa II, and Not I. Differences in cleavage pattern are indicative for the presence or
20 absence of a methylated CpG dinucleotide. Cleavage patterns can be detected directly, or after a further reaction which creates products which are easily distinguishable. Means which detect altered size and/or charge can be used to detect modified products, including but not limited to electrophoresis, chromatography, and mass spectrometry.

Alternatively, the identification of methylated CpG dinucleotides may utilize the
25 ability of the methyl binding domain (MBD) of the MeCP2 protein to selectively bind to methylated DNA sequences (Cross et al, 1994; Shiraishi et al, 1999). The MBD may also be obtained from MBP, MBP2, MBP4, poly-MBD (Jorgensen et al., 2006) or from reagents such as antibodies binding to methylated nucleic acid. The MBD may be immobilized to a solid matrix and used for preparative column chromatography to isolate highly methylated
30 DNA sequences. Variant forms such as expressed His-tagged methyl-CpG binding domain may be used to selectively bind to methylated DNA sequences. Eventually, restriction endonuclease digested genomic DNA is contacted with expressed His-tagged methyl-CpG

binding domain. Other methods are well known in the art and include amongst others methylated-CpG island recovery assay (MIRA). Another method, MB-PCR, uses a recombinant, bivalent methyl-CpG-binding polypeptide immobilized on the walls of a PCR vessel to capture methylated DNA and the subsequent detection of bound methylated DNA by PCR.

Further approaches for detecting methylated CpG dinucleotide motifs use chemical reagents that selectively modify either the methylated or non-methylated form of CpG dinucleotide motifs. Suitable chemical reagents include hydrazine and bisulphite ions. The methods of the invention preferably use bisulphite ions. The bisulphite conversion relies on treatment of DNA samples with sodium bisulphite which converts unmethylated cytosine to uracil, while methylated cytosines are maintained (Furuichi et al., 1970). This conversion finally results in a change in the sequence of the original DNA. It is general knowledge that the resulting uracil has the base pairing behaviour of thymidine which differs from cytosine base pairing behaviour. This makes the discrimination between methylated and non-methylated cytosines possible. Useful conventional techniques of molecular biology and nucleic acid chemistry for assessing sequence differences are well known in the art and explained in the literature. See, for example, Sambrook, J., et al., *Molecular cloning: A laboratory Manual*, (2001) 3rd edition, Cold Spring Harbor, NY; Gait, M.J.(ed.), *Oligonucleotide Synthesis, A Practical Approach*, IRL Press (1984); Hames B.D., and Higgins, S.J. (eds.), *Nucleic Acid Hybridization, A Practical Approach*, IRL Press (1985); and the series, *Methods in Enzymology*, Academic Press, Inc.

Some techniques use primers for assessing the methylation status at CpG dinucleotides. Two approaches to primer design are possible. Firstly, primers may be designed that themselves do not cover any potential sites of DNA methylation. Sequence variations at sites of differential methylation are located between the two primers and visualisation of the sequence variation requires further assay steps. Such primers are used in bisulphite genomic sequencing, COBRA, Ms-SnuPE and several other techniques. Secondly, primers may be designed that hybridize specifically with either the methylated or unmethylated version of the initial treated sequence. After hybridization, an amplification reaction can be performed and amplification products assayed using any detection system known in the art. The presence of an amplification product indicates that a sample hybridized to the primer. The specificity of the primer indicates whether the DNA had been modified or

not, which in turn indicates whether the DNA had been methylated or not. If there is a sufficient region of complementarity, e.g., 12, 15, 18, or 20 nucleotides, to the target, then the primer may also contain additional nucleotide residues that do not interfere with hybridization but may be useful for other manipulations. Examples of such other residues
5 may be sites for restriction endonuclease cleavage, for ligand binding or for factor binding or linkers or repeats. The oligonucleotide primers may or may not be such that they are specific for modified methylated residues.

A further way to distinguish between modified and unmodified nucleic acid is to use oligonucleotide probes. Such probes may hybridize directly to modified nucleic acid or to
10 further products of modified nucleic acid, such as products obtained by amplification. Probe-based assays exploit the oligonucleotide hybridisation to specific sequences and subsequent detection of the hybrid. There may also be further purification steps before the amplification product is detected e.g. a precipitation step. Oligonucleotide probes may be labelled using
15 moieties, radioisotope labelled moieties, bioluminescent moieties, luminescent moieties, chemiluminescent moieties, enzymes, substrates, receptors, or ligands.

In the MSP approach, DNA may be amplified using primer pairs designed to distinguish methylated from unmethylated DNA by taking advantage of sequence differences as a result of sodium-bisulphite treatment (Herman et al., 1996; and WO 97/46705). For
20 example, bisulphite ions modify non-methylated cytosine bases, changing them to uracil bases. Uracil bases hybridize to adenine bases under hybridization conditions. Thus an oligonucleotide primer which comprises adenine bases in place of guanine bases would hybridize to the bisulphite-modified DNA, whereas an oligonucleotide primer containing the guanine bases would hybridize to the non-modified (methylated) cytosine residues in the
25 DNA. Amplification using a DNA polymerase and a second primer yield amplification products which can be readily observed, which in turn indicates whether the DNA had been methylated or not. Whereas PCR is a preferred amplification method, variants on this basic technique such as nested PCR and multiplex PCR are also included within the scope of the invention.

30 As mentioned earlier, a preferred embodiment for assessing the methylation status of the relevant gene requires amplification to yield amplification products. The presence of amplification products may be assessed directly using methods well known in the art. They

simply may be visualized on a suitable gel, such as an agarose or polyacrylamide gel. Detection may involve the binding of specific dyes, such as ethidium bromide, which intercalate into double-stranded DNA and visualisation of the DNA bands under a UV illuminator for example. Another means for detecting amplification products comprises
5 hybridization with oligonucleotide probes. Alternatively, fluorescence or energy transfer can be measured to determine the presence of the methylated DNA.

A specific example of the MSP technique is designated real-time quantitative MSP (QMSP), and permits reliable quantification of methylated DNA in real time or at end point. Real-time methods are generally based on the continuous optical monitoring of an
10 amplification procedure and utilise fluorescently labelled reagents whose incorporation in a product can be quantified and whose quantification is indicative of copy number of that sequence in the template. One such reagent is a fluorescent dye, called SYBR Green I that preferentially binds double-stranded DNA and whose fluorescence is greatly enhanced by binding of double-stranded DNA. Alternatively, labeled primers and/or labeled probes can be
15 used for quantification. They represent a specific application of the well known and commercially available real-time amplification techniques such as TAQMAN®, MOLECULAR BEACONS®, AMPLIFLUOR® and SCORPION® DzyNA®, Plexor™ etc. In the real-time PCR systems, it is possible to monitor the PCR reaction during the exponential phase where the first significant increase in the amount of PCR product
20 correlates to the initial amount of target template.

In specific embodiments, methylation specific PCR/amplification is utilised. This may be carried out in real time or at end point. The real time or end point PCR/amplification may involve use of hairpin primers (Amplifluor), hairpin probes (Molecular Beacons), hydrolytic probes (Taqman), FRET probe pairs (Lightcycler), primers incorporating a hairpin probe
25 (Scorpion), fluorescent dyes (SYBR Green etc.), primers incorporating the complementary sequence of a DNAzyme and a cleavable fluorescent DNAzyme substrate or oligonucleotide blockers, for example.

Real-Time PCR detects the accumulation of amplicon during the reaction. Real-time methods do not need to be utilised, however. Many applications do not require quantification
30 and Real-Time PCR is used only as a tool to obtain convenient results presentation and storage, and at the same time to avoid post-PCR handling. Thus, analyses can be performed only to confirm whether the target DNA is present in the sample or not. Such end-point

verification is carried out after the amplification reaction has finished. This knowledge can be used in a medical diagnostic laboratory to detect a predisposition to, or the incidence of, cancer in a patient. End-point PCR fluorescence detection techniques can use the same approaches as widely used for Real Time PCR. For example, «Gene» detector allows the measurement of fluorescence directly in PCR tubes.

In real-time embodiments, quantitation may be on an absolute basis, or may be relative to a constitutively methylated DNA standard, or may be relative to an unmethylated DNA standard. Methylation status may be determined by using the ratio between the signal of the marker under investigation and the signal of a reference gene where methylation status is known (such as β -actin for example), or by using the ratio between the methylated marker and the sum of the methylated and the non-methylated marker. Alternatively, absolute copy number of the methylated marker gene can be determined.

Suitable controls may need to be incorporated in order to ensure the method chosen is working correctly and reliably. Suitable controls may include assessing the methylation status of a gene known to be methylated. This experiment acts as a positive control to ensure that false negative results are not obtained. The gene may be one which is known to be methylated in the sample under investigation or it may have been artificially methylated, for example by using a suitable methyltransferase enzyme, such as SssI methyltransferase.

Additionally or alternatively, suitable negative controls may be employed with the methods of the invention. Here, suitable controls may include assessing the methylation status of a gene known to be unmethylated or a gene that has been artificially demethylated. This experiment acts as a negative control to ensure that false positive results are not obtained.

Whilst PCR is the preferred nucleic acid amplification technique, other amplification techniques may also be utilised to detect the methylation status of the concerned gene. Such amplification techniques are well known in the art, and include methods such as NASBA (Compton, 1991), 3SR (Fahy et al., 1991) and Transcription Mediated Amplification (TMA). Other suitable amplification methods include the ligase chain reaction (LCR) (Barringer et al, 1990), selective amplification of target polynucleotide sequences (US Patent No. 6,410,276), consensus sequence primed polymerase chain reaction (US Patent No 4,437,975), arbitrarily primed polymerase chain reaction (WO 90/06995), invader technology, strand displacement

technology, and nick displacement amplification (WO 2004/067726). This list is not intended to be exhaustive; any nucleic acid amplification technique may be used provided the appropriate nucleic acid product is specifically amplified. Thus, these amplification techniques may be tied in to MSP and/or bisulphite sequencing techniques for example.

5 In specific embodiments, the methods utilise primers selected from primers comprising, consisting essentially of or consisting of the nucleotide sequences set forth in table 1. Suitable primer pairs can be selected from the primers listed in the table based upon the gene or genes of interest. In specific embodiments, the methods utilise primers selected from primers comprising, consisting essentially of or consisting of the nucleotide sequences
10 set forth as SEQ ID Nos: 1 and 2 (PHACTR3), 4 and 5 (FOX E1), and 7 and 8 (NDRG4) in order to detect methylation status in the DNA. These primers are particularly useful in MSP based methods of detection. Each of the primers covers one or more methylation sites and is specific for the methylated sequence following bisulphite treatment.

 In certain embodiments, the methods utilise probes selected from probes comprising,
15 consisting essentially of or consisting of the nucleotide sequences set forth in table 1. Suitable probes can be selected from the probes listed in the table based upon the gene or genes of interest. In specific embodiments, the methods utilise probes selected from probes comprising, consisting essentially of or consisting of the nucleotide sequences set forth as
20 SEQ ID Nos: 3 (PHACTR3), 6 (FOX E1), and 9 (NDRG4) in order to detect methylation status in the DNA. Each of the probes covers one or more methylation sites and is specific for the methylated sequence following bisulphite treatment. The probes may be utilised in combination with the primers listed above in specific embodiments. The probes may be fluorescently labelled, in particular with a donor and an acceptor (or quencher) fluorophore to permit FRET to occur and allow real-time or end-point detection. An example of a donor
25 moiety is FAM and an example of an acceptor or quencher moiety is DABCYL.

 The methods of the invention are performed using a faecal sample. In certain embodiments, a single faecal sample is utilised as the source of the sample for (a) and (b). However, the sample may need to be split to permit (a) and (b) to be carried out. Thus the sample may need to be treated to differing degrees in order to permit the separate steps to be
30 carried out. As a result, after obtaining the faecal sample, the sample may be apportioned appropriately to allow the DNA and protein testing to be carried out separately.

In the context of these methods of the invention, there is the requirement for appropriate sample processing, since two separate detection techniques may be performed on a single sample. To meet this requirement, the invention provides a method of sample processing, prior to carrying out a method of the invention (tests (a) and (b)), comprising

5 removing a portion of a collected faecal sample and adding the removed portion of the sample to a buffer which prevents denaturation or degradation of blood proteins found in the sample. The faecal sample may be collected at home by the subject. This may involve defecation into a suitable vessel. From this sample is removed a sufficient portion of the sample. This removed portion is then added to a suitable container, which may already

10 contain a buffer. Alternatively, the buffer may be added with the removed portion of the sample or (shortly) afterwards. The removed portion is thus prepared for performance of step (a), namely detecting the presence of blood in the faecal sample, wherein detection of the presence of blood is indicative of a predisposition to, or the incidence of, colorectal cancer, on this sample. The buffer prevents denaturation or degradation of blood proteins found in

15 the sample. Suitable buffers for protein preservation are known in the art and commercially available. The remaining portion of the sample may remain in the vessel in which it was originally collected, prior to carrying out step (b), namely detecting an epigenetic modification in the DNA contained within the faecal sample, wherein detection of the epigenetic modification is indicative of a predisposition to, or the incidence of, colorectal

20 cancer. Suitable buffers for maintaining DNA integrity may be added to the remaining portion of the sample, in certain embodiments. The separated samples may be suitably labelled to ensure that they are paired up correctly during subsequent processing, including data analysis and comparison.

Following collection of the sample and suitable processing, the method may further

25 comprise forwarding or otherwise delivering the removed portion of the collected faecal sample to a laboratory for performing step (a) of the method, as defined herein, on the removed portion of the collected faecal sample. The forwarding or otherwise delivering may occur within any suitable time frame following sample collection. In certain embodiments, the forwarding or otherwise delivering may occur within 6, 12, 24, 48 or 72 hours of sample

30 collection. The method may then further comprise performing step (a) of the method on the removed portion of the collected faecal sample once it has been delivered. As described herein, step (b) may only be performed on a specific subset of samples in which blood is detected at low levels. Thus, the methods of sample processing may involve sorting those

samples with detection of low levels of blood detected in step (a) (as defined herein) for testing in step (b). The appropriate remaining portions of the collected samples in which step (b) is not required (i.e. where a confirmation of the result in step (a) is not required - either because the no blood is detected or the level of blood is above the typically employed threshold (such as 200 ng/ml)) may then be discarded as appropriate.

Similarly, following collection of the sample and suitable processing, the method may further comprise forwarding or otherwise delivering the remaining portion of the collected faecal sample to a laboratory for performing step (b) of the method, as defined herein, on the remaining portion of the collected faecal sample. The forwarding or otherwise delivering may occur within any suitable time frame following sample collection. In certain embodiments, the forwarding or otherwise delivering may occur within 6, 12, 24, 48 or 72 hours of sample collection. The method may then further comprise performing step (b) of the method on the remaining portion of the collected faecal sample once it has been delivered.

In certain embodiments, the forwarding or other delivery of the removed and remaining portions of the collected faecal sample may be carried out to the same location, optionally at the same time. This is the case where the same laboratory is carrying out both steps (a) and (b) which may be the case where the laboratory has the capacity to perform both types of test.

As discussed herein, the faecal samples for use in the invention do not necessarily have to be freshly collected. The discussion above applies mutatis mutandis here. Similarly, a minimal stool sample, including a minimal sample derived from a historical sample as discussed herein, may successfully be employed in the methods of the invention. This is particularly applicable to performing step (b) (i.e. on the remaining portion of the faecal sample). Again, the discussion above applies mutatis mutandis here, including relating to pooling of samples during the DNA extraction process. The requirement for minimal or portioned samples for step (b) may be advantageous by permitting more of the sample to be utilised to perform step (a), potentially improving the sensitivity of step (a).

As shown herein, methylation status determination based upon a panel of at least two genes selected from PHACTR3, NDRG4 and FOXE1 can provide sensitive and specific detection of colorectal cancer. Thus, according to a related aspect, the invention provides a method of detecting a predisposition to, or the incidence of, colorectal cancer in a sample

comprising detecting an epigenetic modification in a panel of at least two genes selected from PHACTR3, NDRG4 and FOXE1, wherein detection of the epigenetic modification in at least one of the genes in the panel is indicative of a predisposition to, or the incidence of, colorectal cancer.

5 It is also shown herein that methylation of LAMA1 and CDO1 is linked to the incidence of colorectal cancer. These genes have not been previously linked to colorectal cancer. Thus, the invention also provides a method of detecting a predisposition to, or the incidence of, cancer (and in particular colorectal cancer) in a sample comprising detecting an epigenetic modification in at least one gene selected from LAMA1 and CDO1, wherein
10 detection of the epigenetic modification in the at least one gene is indicative of a predisposition to, or the incidence of, cancer (and in particular colorectal cancer).

 Evidence is also presented herein that methylation of GPNMB and MMP2 is linked to colorectal cancer, in particular based upon faecal samples. Thus, the invention also relates to a method of detecting a predisposition to, or the incidence of, colorectal cancer (in particular
15 in a faecal sample) comprising detecting an epigenetic modification in at least one gene selected from GPNMB and MMP2, wherein detection of the epigenetic modification in the at least one gene is indicative of a predisposition to, or the incidence of, colorectal cancer.

 As for the first aspect of the invention, the epigenetic modification is often methylation and thus these methods may involve determining the methylation status of the at
20 least one gene or panel of genes. Thus, aberrant methylation, or "hypermethylation", of the gene(s) may be detected. Various methods for determining methylation status are discussed herein, which discussion applies mutatis mutandis to these aspects of the invention. In specific embodiments, methylation specific PCR/amplification is utilised. This may be carried out in real time or at end point. The real time or end point PCR/amplification may
25 involve use of hairpin primers (Amplifluor), hairpin probes (Molecular Beacons), hydrolytic probes (Taqman), FRET probe pairs (Lightcycler), primers incorporating a hairpin probe (Scorpion), fluorescent dyes (SYBR Green etc.), primers incorporating the complementary sequence of a DNase and a cleavable fluorescent DNase substrate or oligonucleotide blockers, for example. The methods may apply suitable primers and probes selected from
30 table 1. In specific embodiments, the methods utilise primers selected from primers comprising, consisting essentially of or consisting of the nucleotide sequences set forth as SEQ ID Nos: 1 and 2 (PHACTR3), 4 and 5 (FOXE1), and 7 and 8 (NDRG4). In further

embodiments, the methods utilise probes selected from probes comprising, consisting essentially of or consisting of the nucleotide sequences set forth as SEQ ID Nos: 3 (PHACTR3), 6 (FOX E1), and 9 (NDRG4). In other embodiments, the methods utilise primers selected from primers comprising the nucleotide sequences set forth as SEQ ID Nos: 28 and 29 (LAMA1) and 34 and 35 (CDO1). In further related embodiments, the methods utilise probes selected from probes comprising the nucleotide sequences set forth as SEQ ID Nos: 30 (LAMA1) and 36 (CDO1). In other embodiments, the methods utilise primers selected from primers comprising the nucleotide sequences set forth as SEQ ID Nos: 22 and 23 (GPNMB) and 31 and 32 (MMP2). In related embodiments, the methods utilise probes selected from probes comprising the nucleotide sequences set forth as SEQ ID Nos: 24 (GPNMB) and 33 (MMP2).

These methods of the invention may be ex vivo or in vitro methods carried out on a test sample. The methods may be non-invasive. The methods may be used to identify any stage of colorectal cancer, including pre-malignancies such as adenomas right through to carcinomas (see the definition of colorectal cancer herein).

The "sample" in which the epigenetic modification is detected may comprise, consist essentially of or consist of a tissue sample, a faecal sample or a blood sample. In preferred embodiments, the sample is a faecal sample. Historical samples (such as those collected at least approximately 1 year ago) and small samples (such as those of approximately 1g) may be useful in the methods of the invention, as discussed herein (which discussion applies mutatis mutandis). In specific embodiments, the tissue sample comprises, consists essentially of or consists of a colon and/or rectum and/or appendix sample. However, the sample may be from any representative tissue sample, body fluid, body fluid precipitate or lavage specimen, as required provided that detection of the epigenetic modification in the sample provides a reliable indicator of colorectal cancer. The sample may be obtained from a human subject. Test samples for diagnostic, prognostic, or personalised medicinal uses can be obtained from surgical samples, such as biopsies or fine needle aspirates, from paraffin embedded tissues, from frozen tumor tissue samples, from fresh tumor tissue samples, from a fresh or frozen body fluid, for example. Non-limiting examples include whole blood, bone marrow, cerebral spinal fluid, peritoneal fluid, pleural fluid, lymph fluid, serum, plasma, urine, chyle, stool, ejaculate, sputum, nipple aspirate, saliva, swabs specimen, wash or lavage fluid and/or brush specimens.

These methods may also include the step of obtaining the test sample, in certain embodiments. The tissue sample or liquid sample comprising the nucleic acid may be lysed or need to be concentrated to create a mixture of biological compounds comprising nucleic acids and other components. Alternatively, the nucleic acid may need to be cleared of
5 proteins or other contaminants, e.g. by treatment with proteinase K. Procedures for lysing or concentrating biological samples are known by the person skilled in the art and can be chemical, enzymatic or physical in nature. A combination of these procedures may be applicable as well. For instance, lysis may be performed using ultrasound, high pressure, shear forces, alkali, detergents or chaotropic saline solutions, or proteases or lipases. For the
10 lysis procedure to obtain nucleic acids, or concentrating nucleic acid from samples, reference may be made to Sambrook, J., et al., *Molecular cloning: A Laboratory Manual*, (2001) 3rd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York Ausubel, F.M., et al., *Current Protocols in Molecular Biology* (1987), J. Wiley and Sons, New York.

The test sample is generally obtained from a (human) subject suspected of being
15 tumorigenic. Alternatively the test sample is obtained from a subject undergoing routine examination and not necessarily being suspected of having a disease. Thus patients at risk can be identified before the disease has a chance to manifest itself in terms of symptoms identifiable in the patient.

Alternatively the sample is obtained from a subject undergoing treatment, or from
20 patients being checked for recurrence of disease.

Cancers characterised by hypermethylation of tumour suppressor genes may be treated by reducing methylation within the tumour cells. Various agents may be employed for this purpose, including DNA demethylating agents, DNA methyltransferase inhibitors and HDAC inhibitors. Accordingly, the invention also provides a method for predicting the
25 likelihood of successful treatment of colorectal cancer with a DNA demethylating agent and/or a DNA methyltransferase inhibitor and/or HDAC inhibitor comprising detecting an epigenetic modification in: (a) a panel of at least two genes selected from PHACTR3, NDRG4 and FOXE1 ,

(b) at least one gene selected from LAMA1 and CDO1; or

(c) at least one gene selected from GPNMB and MMP2 (in a faecal sample) wherein detection of the epigenetic modification in at least one of the genes in the panel or in the at least one gene is indicative that the likelihood of successful treatment is higher than if the epigenetic modification is not detected.

5 Similarly, the invention provides a method for predicting the likelihood of resistance to treatment of colorectal cancer with a DNA demethylating agent and/or DNA methyltransferase inhibitor and/or HDAC inhibitor comprising detecting an epigenetic modification in (a) a panel of at least two genes selected from PHACTR3, NDRG4 and FOXE1 ,

10 (b) at least one gene selected from LAMA1 and CDO1; or

(c) at least one gene selected from GPNMB and MMP2 (in a faecal sample) wherein detection of the epigenetic modification in at least one of the genes in the panel or in the at least one gene is indicative that the likelihood of resistance to treatment is lower than if the epigenetic modification is not detected.

15 Furthermore, there is provided a method of selecting a suitable treatment regimen for colorectal cancer comprising detecting an epigenetic modification in (a) a panel of at least two genes selected from PHACTR3, NDRG4 and FOXE1, (b) at least one gene selected from LAMA1 and CDO1 ; or

20 (c) at least one gene selected from GPNMB and MMP2 (in a faecal sample) wherein detection of the epigenetic modification in at least one of the genes in the panel or in the at least one gene results in selection of a DNA demethylating agent and/or a DNA methyltransferase inhibitor and/or a HDAC inhibitor for treatment and wherein if the epigenetic modification is not detected, a DNA demethylating agent and/or a DNA methyltransferase inhibitor and/or a HDAC inhibitor is not selected for treatment.

25 In a related aspect, the invention provides a method for monitoring treatment of colorectal cancer with a DNA demethylating agent and/or a DNA methyltransferase inhibitor and/or HDAC inhibitor comprising detecting an epigenetic modification in

(a) a panel of at least two genes selected from PHACTR3, NDRG4 and FOXE1,

(b) at least one gene selected from LAMA1 and CDO1 ; or (c) at least one gene selected from GPNMB and MMP2 (in a faecal sample) wherein detection of a reduction in the (levels of the) epigenetic modification in at least one of the genes in the panel or in the at least one gene as treatment progresses is indicative of successful treatment. Thus, the epigenetic modification may be measured at the start of the treatment and then once or more following treatment, or as treatment progresses, in order to determine if the treatment is achieving the desired effect. A return to lower levels of methylation of the genes is considered indicative of effective treatment. Thus, the method may involve testing samples taken at various time points in order to determine the effect of the treatment. A threshold may be set (i.e. a level of reduction in the epigenetic modification) at which treatment is considered successful and may, therefore, be reduced or terminated.

For all of the relevant methods (pharmacogenetic methods, treatment regimen methods, monitoring methods and methods of treatment) of the invention, the DNA demethylating agent may be any agent capable of alleviating hypermethylation of the relevant genes (and thus up regulating transcription of the genes). The DNA methyltransferase inhibitor may be any suitable inhibitor of DNA methyltransferase activity or expression which is suitable for treating cancer in the presence of methylation of the at least one gene. The DNA methyltransferase inhibitor may, be one which reduces expression of DNMT genes, such as suitable antisense molecules, or double stranded RNA molecules, such as siRNA and miRNA molecules which mediate RNAi for example. The design of a suitable siRNA molecule is within the capability of the skilled person and suitable molecules can be made to order by commercial entities (see for example, www.ambion.com). In embodiments, the DNA methyltransferase gene is (human) DNMT1.

Alternatively, the agent may be a direct inhibitor of DNMTs. Examples include modified nucleotides such as phosphorothioate modified oligonucleotides (fig 6 of Villar-Garea, A. And Esteller, M. DNA demethylating agents and chromatin-remodelling drugs: which, how and why? *Current Drug Metabolism*, 2003, 4, 11-31) and nucleosides and nucleotides such as cytidine analogues. Suitable examples of cytidine analogues include 5-azacytidine, 5-aza-2'-deoxycytidine, 5-fluouro-2'-deoxycytidine, pseudoisocytidine, 5,6-dihydro-5-azacytidine, 1- β -D- arabinofuranosyl-5-azacytosine (known as fazabarine) (see figure 4 of Villar-Garea, A. And Esteller, M. DNA demethylating agents and chromatin-

remodelling drugs: which, how and why? Current Drug Metabolism, 2003, 4, 11-31). The DNA methyltransferase inhibitor may comprise Decitabine.

Additional DNMT inhibitors include S-Adenosyl-Methionine (SAM) related compounds like ethyl group donors such as L-ethionine and non-alkylating agents such as S-adenosyl-homocysteine (SAH), sinefungin, (S)-6-methyl-6-deaminosine fungin, 6-deaminosinefungin, N4-adenosyl-N4-methyl-2,4-diaminobutanoic acid, 5'-methylthio-5'-deoxyadenosine (MTA) and 5'-amino-5'-deoxyadenosine (Villar-Garea, A. And Esteller, M. DNA demethylating agents and chromatin-remodelling drugs: which, how and why? Current Drug Metabolism, 2003, 4, 11-31). Useful DNMT inhibitors in the present invention
10 comprise, consists essentially of or consists of 5-azacytidine and/or zebulaine.

Further agents which may alter DNA methylation and which may, therefore, be useful in the present invention as DNA demethylating agents include organohalogenated compounds such as chloroform etc, procianamide, intercalating agents such as mitomycin C, 4-aminobiphenyl etc, inorganic salts of arsenic and selenium and antibiotics such as kanamycin,
15 hygromycin and cefotaxim (Villar-Garea, A. And Esteller, M. DNA demethylating agents and chromatin-remodelling drugs: which, how and why? Current Drug Metabolism, 2003, 4, 11-31).

Many HDAC inhibitors are similarly known in the art. Examples include carboxylic acid based HDAC inhibitors such as valproate and/or butyrate and hydroxamic acid based
20 HDAC inhibitors such as trichostatin A, suberoyl hydroxamic acid (SBHA), 6-(3-chlorophenylureido)caproic hydroxamic acid (3-CI-UCHA), m-carboxycinnamic acid bishydroxylamide (CBHA), suberoylanilide hydroxamic acid (SAHA), azelaic bishydroxamic acid (ABHA), pyroxamide, aromatic sulfonamides bearing a hydroxamic acid group and cyclic-hydroxamic-acid containing peptides.

25 For each of these additional aspects, the embodiments and optional features of the methods of the invention apply mutatis mutandis and are not repeated for reasons of conciseness. Thus, all methods of detecting an epigenetic modification in the DNA, in particular in the specified genes, including expression and re-expression based assays, may be employed appropriately.

In a further related aspect, the invention provides a method of treating colorectal cancer in a subject comprising administration of a DNA demethylating agent and/or a DNA methyltransferase inhibitor and/or a HDAC inhibitor wherein the subject has been selected for treatment on the basis of a method of the invention. Thus, detecting an epigenetic
5 modification in

(a) a panel of at least two genes selected from PHACTR3, NDRG4 and FOXE1 ,

(b) at least one gene selected from LAMA1 and CDO1; or

(c) at least one gene selected from GPNMB and MMP2 (in a faecal sample) may be used in order to direct treatment of the subject (from which the sample was taken).

10 The invention also relates to corresponding kits for carrying out the methods of the invention. Thus, the invention provides a kit for detecting a predisposition to, or the incidence of, colorectal cancer in a faecal sample comprising:

(a) means for detecting the presence of blood in the faecal sample, wherein detection of the presence of blood is indicative of a predisposition to, or the incidence of, colorectal
15 cancer, and

(b) means for detecting an epigenetic modification in the DNA contained within the faecal sample, wherein detection of the epigenetic modification is indicative of a predisposition to, or the incidence of, colorectal cancer.

As for the corresponding methods, in certain embodiments, the epigenetic
20 modification is detected in at least one gene selected from PHACTR3, NDRG4, FOXE1, GATA4, GPNMB, TFPI2, SOX17, SYNE1, LAMA, MMP2, OSMR, SFRP2 and CDO1 and thus the means for detecting an epigenetic modification in the DNA are means for detecting an epigenetic modification in at least one gene selected from PHACTR3, NDRG4, FOXE1, GATA4, GPNMB, TFPI2, SOX17, SYNE1, LAMA, MMP2, OSMR, SFRP2 and CDO1 In
25 further embodiments, the epigenetic modification is detected in at least one gene selected from PHACTR3, NDRG4 and FOXE1 and thus the means for detecting an epigenetic modification in the DNA are means for detecting an epigenetic modification in at least one gene selected from PHACTR3, NDRG4 and FOXE1. The epigenetic modification may be detected in a panel of at least two genes selected from PHACTR3, NDRG4 and FOXE1 ,

with detection of the epigenetic modification in at least one of the genes providing an indication of a predisposition to, or incidence of, colorectal cancer. Means may be provided for detecting an epigenetic modification in a panel of genes comprising, consisting essentially of or consisting of PHACTR3, NDRG4 and FOXE1, NDRG4 and FOXE1, PHACTR3 and
5 NDRG4, or PHACTR3 and FOXE1. In some embodiments, the means for detecting an epigenetic change in the panel of genes enable the detection to be carried out in a single reaction. Thus the means may permit multiplexing.

In further embodiments, the epigenetic modification is detected in at least one gene selected from LAMA1 and CDO1 and thus the means for detecting an epigenetic
10 modification in the DNA are means for detecting an epigenetic modification in at least one gene selected from LAMA1 and CD01. Suitable primers and probes are set forth in table 1.

In further embodiments, the epigenetic modification is detected in at least one gene selected from GPNMB and MMP2 and thus the means for detecting an epigenetic modification in the DNA are means for detecting an epigenetic modification in at least one
15 gene selected from GPNMB and MMP2. Suitable primers and probes are set forth in table 1.

As for the methods, the epigenetic modification is often methylation. Thus, the means for detecting an epigenetic modification in the DNA contained within the faecal sample may comprise, consist essentially of or consist of primers and/or probes which permit the methylation status of the DNA to be determined directly. In specific embodiments, the
20 primers are selected from primers comprising, consisting essentially of or consisting of the nucleotide sequences set forth in table 1. Suitable primer pairs can be selected from the primers listed in the table based upon the gene or genes of interest. In specific embodiments, the kits incorporate primers selected from primers comprising, consisting essentially of or consisting of the nucleotide sequences set forth as SEQ ID Nos: 1 and 2 (PHACTR3), 4
25 and 5 (FOXE1), and 7 and 8 (NDRG4). In further specific embodiments, the probes are selected from probes comprising, consisting essentially of or consisting of the nucleotide sequences set forth in table 1. Suitable probes can be selected from the probes listed in the table based upon the gene or genes of interest. In specific embodiments, the kits incorporate probes selected from probes comprising, consisting essentially of or consisting of the
30 nucleotide sequences set forth as SEQ ID Nos: 3 (PHACTR3), 6 (FOXE1), and 9 (NDRG4).

The kit may contain any suitable means for allowing detection of blood in a faecal sample. In particular embodiments, the means for detecting the presence of blood in the faecal sample comprise means for detection of haemoglobin in the faecal sample. These may be chromogenic or immunochemical means. Thus, gum guaiac may be incorporated in the kits for chromogenic detection. Alternatively suitable anti-haemoglobin antibodies, as discussed herein, may be incorporated in the kits of the invention. These components may be provided together with suitable buffers etc. as would be readily appreciated by one skilled in the art.

The kits of the invention may also contain further elements to facilitate sample collection and processing. Thus in certain embodiments, the kit further comprises a sealable vessel for collection of a faecal sample. This vessel may be of a size and construction to permit a subject to directly defecate into the vessel. There may also be provided an additional container to which a removed portion of the sample may be added to allow step (a) to be performed on this separated sample. As mentioned in the methods section, this container may contain or be supplied with an appropriate buffer for protein preservation (to prevent denaturation or degradation of proteins). The kit may also contain suitable means for transfer of the removed portion of the sample to the second container. In view of the fact that the invention may be performed using only a small portion of the (total collected) faecal sample, as discussed herein (for example using as little as approximately 1 g of stool to perform DNA extraction), the second container may be suitably dimensioned to contain such a minimal/portioned sample. The second container may be provided with a suitable collection device, adapted to retrieve and/or deposit an appropriate minimal/portioned sample (as described herein, of approximately 5, 4, 3, 2 or 1g or less). Suitable tubes and spoons for inclusion in such a kit are known in the art and commercially available. The spoons may be measuring spoons and may be integrated into the tubes in certain embodiments. The container may be dimensioned such that a suitable volume of homogenization buffer (as discussed herein, which discussion applies mutatis mutandis) may be added to the minimal/portioned sample added to the container.

In further embodiments, the kit, or more specifically the means for detecting an epigenetic modification in the DNA, further comprises means for processing a faecal sample. The means for processing a faecal sample comprises a homogenization buffer in certain embodiments. Suitable homogenization buffers are known in the art and commercially

available. In related embodiments, the means for processing a faecal sample comprises reagents for extraction/isolation/concentration/purification of DNA. As an example, the QIAamp DNA stool kit available from Qiagen includes suitable components for purification of total DNA from fresh or frozen faecal samples.

5 In order to permit determination of the methylation status of the DNA, the kits may further comprise a reagent which selectively modifies unmethylated cytosine residues in the DNA contained in the sample to produce detectable modified residues but which does not modify methylated cytosine residues. As discussed above, this permits sequence differences to be detected as an indication of the methylation status of the DNA. Any suitable reagent
10 may be employed. Many examples are known in the art and commercially available. In certain embodiments, the reagent comprises a bisulphite reagent. More specifically, the bisulphite reagent may comprise, consist essentially of or consist of sodium bisulphite.

In a related aspect, the invention also provides a kit for any of:

- (a) detecting a predisposition to, or the incidence of, colorectal cancer in a sample
- 15 (b) monitoring treatment of colorectal cancer with a DNA demethylating agent and/or a DNA methyltransferase inhibitor and/or HDAC inhibitor
- (c) predicting the likelihood of successful treatment of colorectal cancer with a DNA demethylating agent and/or a DNA methyltransferase inhibitor and/or HDAC inhibitor
- (d) predicting the likelihood of resistance to treatment of colorectal cancer with a
20 DNA demethylating agent and/or DNA methyltransferase inhibitor and/or HDAC inhibitor;
 or
- (e) selecting a suitable treatment regimen for colorectal cancer comprising means for detecting an epigenetic modification in a panel of at least two genes selected from PHACTR3, NDRG4 and FOXE1.

25 As discussed herein, detection of the methylation status of this panel of genes provides a sensitive and specific means for detecting colorectal cancer. In certain embodiments, the means for detecting an epigenetic modification in a panel of at least two genes selected from PHACTR3, NDRG4 and FOXE1 comprise primers and/or probes which

permit the methylation status of the genes to be determined directly. In specific embodiments, the primers are selected from primers comprising, consisting essentially of or consisting of the nucleotide sequences set forth as SEQ ID Nos: 1 and 2 (PHACTR3), 4 and 5 (FOXE1), and 7 and 8 (NDRG4). In further embodiments, the probes are selected from probes
5 comprising, consisting essentially of or consisting of the nucleotide sequences set forth as SEQ ID Nos: 3 (PHACTR3), 6 (FOXE1), and 9 (NDRG4).

Similarly, the invention also provides a kit for any of:

- (a) detecting a predisposition to, or the incidence of, colorectal cancer in a sample
- (b) predicting the likelihood of successful treatment of colorectal cancer with a DNA
10 demethylating agent and/or a DNA methyltransferase inhibitor and/or HDAC inhibitor
- (c) predicting the likelihood of resistance to treatment of colorectal cancer with a DNA demethylating agent and/or DNA methyltransferase inhibitor and/or HDAC inhibitor;
- or (d) selecting a suitable treatment regimen for colorectal cancer comprising means for detecting an epigenetic modification in at least one gene selected from LAMA1 and CDO1

15 As discussed herein, detection of the methylation status of these genes has been shown herein to provide a sensitive and specific means for detecting colorectal cancer. In certain embodiments, the means for detecting an epigenetic modification in at least one gene selected from LAMA1 and CDO1 comprise primers and/or probes which permit the methylation status of the at least one gene to be determined directly. In specific embodiments,
20 the primers are selected from primers selected from primers comprising, consisting essentially of or consisting of the nucleotide sequences set forth as SEQ ID Nos: 28 and 29 (LAMA1) and 34 and 35 (CDO1). In further embodiments, the probes are selected from probes comprising, consisting essentially of or consisting of the nucleotide sequences set forth as SEQ ID Nos: 30 (LAMA1) and 36 (CDO1).

25 As for the methods, the kits are preferably employed in the context of faecal samples. Thus, the kit further comprises means for processing a faecal sample in certain embodiments. In view of the fact that the invention may be performed using only a small portion of the (total collected) faecal sample, as discussed herein (for example using as little as approximately 1g of stool to perform DNA extraction), the kits may incorporate a container

suitably dimensioned to contain such a minimal/portioned sample. The container may be provided with a suitable collection device, adapted to retrieve and/or deposit an appropriate minimal/portioned sample (as described herein, of approximately 5, 4, 3, 2 or 1g or less). Suitable tubes and spoons for inclusion in such a kit are known in the art and commercially available. The spoons may be measuring spoons and may be integrated into the tubes in certain embodiments. The container may be dimensioned such that a suitable volume of homogenization buffer (as discussed herein, which discussion applies mutatis mutandis) may be added to the minimal/portioned sample added to the container.

The invention also provides a kit for any of:

- (a) detecting a predisposition to, or the incidence of, colorectal cancer in a sample
- (b) predicting the likelihood of successful treatment of colorectal cancer with a DNA demethylating agent and/or a DNA methyltransferase inhibitor and/or HDAC inhibitor
- (c) predicting the likelihood of resistance to treatment of colorectal cancer with a DNA demethylating agent and/or DNA methyltransferase inhibitor and/or HDAC inhibitor;
- or (d) selecting a suitable treatment regimen for colorectal cancer comprising means for detecting an epigenetic modification in at least one gene selected from GPNMB and MMP2 and means for processing a faecal sample.

As discussed herein, detection of the methylation status of these genes has been shown herein to provide a sensitive and specific means for detecting colorectal cancer in the context of faecal samples. In certain embodiments, the means for detecting an epigenetic modification in at least one gene selected from GPNMB and NMP1 comprise primers and/or probes which permit the methylation status of the at least one gene to be determined directly. In specific embodiments, the primers are selected from primers selected from primers comprising, consisting essentially of or consisting of the nucleotide sequences set forth as SEQ ID Nos: 22 and 23 (GPNMB) and 31 and 32 (MMP2). In further embodiments, the probes are selected from probes comprising, consisting essentially of or consisting of the nucleotide sequences set forth as SEQ ID Nos: 24 (GPNMB) and 33 (MMP2).

In specific embodiments of these kits of the invention which involve means for processing a faecal sample, the means for processing a faecal sample comprises a sealable

vessel for collection of a faecal sample. This vessel may be of a size and construction to permit a subject to directly defecate into the vessel. In view of the fact that the invention may be performed using only a small portion of the (total collected) faecal sample, as discussed herein (for example using as little as approximately 1 g of stool to perform DNA extraction),
5 the kits may incorporate a container suitably dimensioned to contain such a minimal/portioned sample. The container may be provided with a suitable collection device, adapted to retrieve and/or deposit an appropriate minimal/portioned sample (as described herein, of approximately 5, 4, 3, 2 or 1g or less).

Suitable tubes and spoons for inclusion in such a kit are known in the art and
10 commercially available. The spoons may be measuring spoons and may be integrated into the tubes in certain embodiments. The container may be dimensioned such that a suitable volume of homogenization buffer (as discussed herein, which discussion applies mutatis mutandis) may be added to the minimal/portioned sample added to the container.

In further embodiments, the means for processing a faecal sample comprises a
15 homogenization buffer in certain embodiments. Suitable homogenization buffers are known in the art and commercially available. In related embodiments, the means for processing a faecal sample may (further) comprise reagents for extraction/isolation/concentration/purification of DNA from the faecal sample. As an example, the QIAamp DNA stool kit available from Qiagen includes suitable components for
20 purification of total DNA from fresh or frozen faecal samples.

In order to permit determination of the methylation status of the panel of genes, the kits may further comprise a reagent which selectively modifies unmethylated cytosine residues in the DNA contained in the sample to produce detectable modified residues but which does not modify methylated cytosine residues. As discussed above, this permits
25 sequence differences to be detected as an indication of the methylation status of the DNA. Any suitable reagent may be employed. Many examples are known in the art and commercially available. In certain embodiments, the reagent comprises a bisulphite reagent. More specifically, the bisulphite reagent may comprise, consist essentially of or consist of sodium bisulphite.

30

EXPERIMENTAL SECTION

Example 1

Sample collection and processing

A standardized multicenter screening trial (The Netherlands) was initiated in 2006. In this trial, non symptomatic subjects aged 50 or above are screened with colonoscopy, FOBT and real-time MSP using DNA from stool and blood. In addition, prospectively collected stool samples from multiple centers (Germany and The Netherlands) were used. In these trials, symptomatic patients, attending a Gastroenterology clinic and ultimately diagnosed with CRC, provided a stool sample for use in real-time MSP. From the ongoing trials 111 stool samples were available for the present study. 3 main categories of stool samples were used: 38 samples with no suspicious findings, 10 adenomas and 63 samples from patients covering all stages of CRC. After defecation in a special bucket, an iFOBT samples was taken (Eiken device) and the patients subsequently added 250 ml of stool homogenization buffer (Amresco, Solon, Ohio, USA) to the sample. Samples were shipped to the laboratory and further processed within 72 hours after defecation. Stool homogenization buffer was added to a ratio 1 :7, and the samples were homogenized and aliquoted in portions of 32 ml.

iFOBT

The OC-Hemodia 'Eiken' was used to detect faecal occult blood when screening for early identification of colon cancer

DNA extraction from stool

Single aliquots (32 ml containing the equivalent of 4 g of stool) were centrifuged for 5 minutes at 2540 rcf at 20°C. The supernatant was retained and centrifuged a second time (10 minutes at 16500 rcf at 4°C). 22 ml of the supernatant obtained following the second centrifugation step was incubated with 5 µl Rnase A for 60 minutes at 37°C. Total DNA was then SodiumAcetate (pH 5.2) - isopropanol precipitated and washed with 70% ethanol. This "crude DNA" was resuspended in 4 ml 1x TE (pH 7.4). For set A (QIAamp DNA Stool Mini Kit): Add 1.6ml ASL Buffer to 300 µl "crude DNA" and vortex. The samples were centrifuged to pellet remaining stool particles. 1.4 ml of this supernatant was transferred into a new microcentrifuge tube. One InhibitEX Tablet was dissolved in each sample before a

1 min incubation step to allow inhibitors to adsorb to the InhibitEX matrix. The samples were then centrifuged to pellet all remaining stool particles and inhibitors bound to InhibitEX matrix. The supernatant was transferred into a new microcentrifuge tube. 25 µl of proteinase K was added to 600 µl of sample supernatant before adding 600 µl of AL Buffer. The tubes
5 are incubated at 70°C for 10 min. 600 µl of ethanol (96-100%) were added to the lysate, and mix by vortexing. Carefully apply 3x600 µl of lysate to QIAamp spin columns, centrifuge and discard the tube containing the filtrate. Carefully open the QIAamp spin column and add 500 µl of AW1 Buffer, centrifuge and discard the collection tube containing the filtrate. Carefully open the QIAamp spin column and add 500 µl of AW2 Buffer, centrifuge and discard
10 the collection tube containing the filtrate. Transfer the QIAamp spin column into a new microcentrifuge tube, open the QIAamp spin column, add 50 µl of AE Buffer onto the membrane, incubate for 1 min at room temperature, and then centrifuge to elute DNA. For set B (QIAamp DNA Stool Midi Kit): Add 1.5 ml ASL buffer to 2 ml of "Crude DNA". Add 1 InhibitEX Tablet to each sample and vortex IMMEDIATELY and continuously for 1 min or
15 until the tablet is completely suspended. Incubate suspension for 1 min at room temperature to allow inhibitors to adsorb to the InhibitEX matrix. Centrifuge sample to pellet stool particles and inhibitors bound to InhibitEX matrix. Collect the supernatant and transfer it into a new 15 ml centrifuge tube, discard the pellet.

Add 150 µl proteinase K to 2 ml of the supernatant, mix well, add 2.4 ml of AL
20 Buffer and vortex for 15 s. Incubate at 70°C for 10 min. Add 2 ml ethanol (96-100%) to the sample, and mix by inverting the tube 10 times, followed by additional vigorous shaking. In order to ensure efficient binding, it is essential that the sample is mixed thoroughly after addition of ethanol to yield a homogeneous solution.

Carefully transfer 3.3 ml of the sample onto the QIAamp Midi column placed in a 15
25 ml centrifuge tube and centrifuge at 1850 x g (3000 rpm) for 3 min, and discard the filtrate. Place the QIAamp midi column back into the 15 ml centrifuge tube. Load the remainder of the sample onto the QIAamp Midi column, centrifuge again at 1850 x g (3000 rpm) for 3 minutes, and discard the filtrate. Place the QIAamp Midi column back into the 15 ml centrifuge tube, add 2 ml of AW1 Buffer, centrifuge at 4500 x g (5000 rpm) for 1 min, add
30 2 ml of AW2 Buffer to the QIAamp Midi column, centrifuge at 4500 x g (5000 rpm) for 1 min, and discard the filtrate. Place the QIAamp Midi column in a clean 15 ml centrifuge tube,

centrifuge for 1 min to dry the column, place the QIAamp Midi column in a clean 15 ml centrifuge tube, and discard the collection tube containing the filtrate.

Add 200 µl of AE Buffer directly onto the membrane of the QIAamp Midi column, incubate at room temperature for 5 min, and centrifuge at 4500 x g (5000 rpm) for 2 min.

- 5 Reload the same 200µl onto the membrane, incubate at room temperature for 5 min, and centrifuge at 4500 x g (5000 rpm) for 2 min to elute the DNA.

DNA modification

- 1.5 µg of DNA were subjected to bisulfite modification in 96-wells format on a pipetting robot (Tecan), using the EZ-96DNA Methylation kit (Zymo Research), according to the manufacturer's protocol. Basically, aliquots of 45 µl were mixed with 5 µl of M-Dilution Buffer and incubated at 37°C for 15 minutes shaking at 1100 rpm. Then 100 µl of the diluted CT Conversion Reagent was added and samples were incubated at 70°C for 3 hours, shaking at 1100 rpm in the dark. After conversion, the samples were desalted by incubation on ice for 10 minutes and addition of 400 µl of M-Binding buffer. The samples were loaded on a Zymo-Spin I Column in a collection tube and after centrifugation washed with 200 µl of M-Wash Buffer. 200 µl of M-Desulphonation Buffer was put onto the column and incubated at room temperature for 15 minutes. After centrifugation of the columns, they were washed twice with 200 µl of M-Wash Buffer. Finally, the DNA was washed from the column in 50 µl Tris-HCl 1mM pH8.0 and stored at -80°C, until further processing.

20 *DNA amplification*

- Real-time MSP was applied on a 7900HT fast real-time PCR system (Applied Biosystems). 5ul or 10ul of the modified DNA was added to a PCR mix (total volume 25 or 50ul) containing buffer (16.6mM (NH₄)₂SO₄, 67 mM Tris (pH 8.8), 6.7 mM MgCl₂, 10 mM β-mercaptoethanol), dNTPs (5 mM), forward primer (6 ng), reverse primer (18 ng), molecular beacon (0.16 µM), BSA (0.1 µg), and Jumpstart DNA Taq polymerase (0.4 units; Sigma Aldrich). The primer sequences and molecular beacon sequences used for each of the genes are summarized in table 1. Cycle program used was as follows: 5 minutes 95°C, followed by 45 cycles of 30 seconds 95°C, 30 seconds 57°C (51 °C for APC), and 30 seconds 72°C, followed by 5 minutes 72°C. A standard curve (2x10⁶ - 20 copies) was included to

determine copy numbers of unknown samples by interpolation of their Ct values to the standard curve.

RESULTS

Table 1: Primers sequences and beacon sequences (for sample sets A and B)

Gene	Primer or probe	Nucleotide sequence (including labels on probe)	SEQ ID NO:
PHACTR	forward primer	5' - TTATTTTGGAGCGGTTTC - 3'	1
	reverse primer	5' - GAATACTCTAATTCCACGCGACT - 3'	2
	beacon	5'-FAM- CGACATGCGGGTTCGGTCGGCGCGGGGCATGTCG-3'-DABCYL	3
FOX1	forward primer	5' - TTTGTTTCGTTTTCGATTGTTTC - 3'	4
	reverse primer	5' - TAACGCTATAAACTCCTACCGC - 3'	5
	beacon	5'-FAM- CGTCTCGTCGGGGTTCGGGCGTATTTTTCAGGTAGGCGAGACG -3'-DABCYL	6
NDRG4	forward primer	5' - GTATTTTAGTCGCGTAGAAGGC - 3'	7
	reverse primer	5' - AATTTAACGAATATAAACGCTCGAC - 3'	8
	beacon	5'-FAM-CGACATGCCCCGAACGAACCGCATCCCTGCATGTCG-3'-DABCYL	9
GATA4	Forward primer	5'-AGGTTAGTAGCGTTTTCAGGGTC-3'	10
	Reverse primer	5'-ACGACGACGAAACCTCTCG-3'	11
	beacon	5'-FAM-CGACATGCCTCGCGACTCGAATCCCCGACCCAGCATGTCG-DABCYL-3'	12
OSMR	Forward primer	5' - TTTGGTCGGGGTAGGAGTAGC - 3'	13
	Reverse primer	5' - CGAACTTTACGAACGAACGAAC - 3'	14
	beacon	5'-FAM-CGACATGCCCCGATCCCGCGCGCAGCATGTCG-3'-DABCYL	15
SYNE1	Forward primer	5'-GTTGGGTTTTCGTAGTTTGTAGATCGC-3'	16
	Reverse primer	5'-CTACGCCCAAACCTCGACG-3'	17
	beacon	5'-FAM-CGACATGCCCCGCGCTATCGCCGAAATCGCATGTCG-DABCYL-3'	18
SFRP2	Forward primer	5' - GGGTCGGAGTTTTTCGGAGTTGCGC - 3'	19
	Reverse primer	5' - CCGCTCTCTTCGTAAATACGACTCG - 3'	20
	beacon	5'-FAM- CGACATGCGGTGTTTCGTTTTCGCGTTTTCAGTCGTCGGGCATGTCG - DABCYL-3'	21
GPNMB	Forward primer	5'-GGTCGTAGTCGTAGTCGGG-3'	22
	Reverse primer	5'-CCGCAAAAACCTAAAACGTAA-3'	23
	beacon	5'-FAM-CGACATGCGGTTTTTTGGGTCGGGGCGCGGCATGTCG-DABCYL-3'	24
SOX17	Forward primer	5'-GAGATGTTTCGAGGGTTGC-3'	25
	Reverse primer	5'-CCGCAATATCACTAAACCGA-3'	26
	beacon	5'-FAM-CGACATGCGTTCGTGTTTGGTTTGTGCGCGGTTTGGCATGTCG DABCYL-3'	27
LAMA1	Forward primer	5'-TTTTTAGATTATCGAGTGGCG-3'	28
	Reverse primer	5'-CGAACTCACCTCTCTACCGAC-3'	29
	beacon	5'-CGACATGCCAAAAACACGCCCCCGCGCATGTCG-3'	30

5

The performance of combinations of three methylation markers was also investigated. Methylated copies of the genes were quantified in the available stool samples by real-time MSP on a 7900HT fast real-time PCR system (Applied Biosystems). Table 3 shows the results and lists the cut-off (copies) applied. The best combinations had 100% specificity,
 5 70% sensitivity for CRC.

Table 3: Performance of 3 methylation marker combinations in set A (top 3 rows give the cutoffs, empty cells denote that the gene was not used). A sample is scored as positive if any one marker is positive.

NDRG4 (copies)	2	2		2
FOXE1 (copies)	0	0	0	
PHACTR (copies)	100		100	100
Spec (n=21)	100%	100%	100%	100%
Sens (n=23)	70%	70%	52%	55%

10 Performance of FIT in fecal samples (set A)

FIT was evaluated in the same fecal samples. The performance in fecal samples is shown in Table 4. A specificity of 95% and sensitivity of 78% was obtained.

Table 4: Performance of FIT in fecal samples set A

	FIT
Cutoff (ng/ml)	100
Spec (n=21)	95%
Sens (n=23)	78%

15

Performance of the 3 methylation marker combination AND FIT in fecal samples set A

The performance of combination of the methylation markers with FIT was investigated. Methylated copies of the genes were quantified in the available stool samples by real-time MSP on a 7900HT fast real-time PCR system (Applied Biosystems). Table 5 shows the results and lists the cut-off (copies) applied.

Table 5: Performance of the methylation marker combinations in set A. A sample is scored as positive if any one marker is positive.

Gene	cutoffs (copies)	Methylation marker only		Methylation markers plus FIT (100 ng/ml cutoff)	
		Spec (n=21)	Sens (n=23)	Spec (n=21)	Sens (n=23)
GATA4	10	90%	52%	86%	87%
GPNUMB	100	100%	39%	95%	87%
TFPI2	100	100%	48%	95%	91%
FoxE1	5	100%	39%	95%	87%
SOX17	10	90%	35%	86%	87%
SYNE1	3	90%	43%	86%	91%
NDRG4	2	100%	61%	95%	87%
LAMA	40	100%	30%	95%	83%
MMP2	10	95%	39%	90%	87%

PHACTR	100	100%	43%	95%	87%
OSMR	1	95%	22%	90%	83%
CDO1	10	95%	13%	90%	83%

10 Performance of the methylation marker combination AND FIT in fecal samples set A

The performance of a combination of the methylation markers with FIT was investigated, the results are shown in table 6.

Table 6: Performance of 3 methylation marker combinations in set A (top 4 rows give the cutoffs, empty cells denote that the gene was not used). A sample is scored as positive if any one marker is positive.

FIT (ng/ml)	100	100	100	100
NDRG4 (copies)	2	2		2
FOX E1 (copies)	0	0	0	
PHACTR (copies)	100		100	100
Spec (n=21)	95%	95%	95%	95%
Sens (n=23)	96%	96%	91%	91%

Performance of methylation markers in fecal samples (set B)

Seven methylation markers (NDRG4, FoxE1, PHACTR, GATA4, OSMR, SYNE1 , SFRP2) were evaluated in fecal samples. Methylated copies of these genes were quantified in the available stool samples by real-time MSP on a 7900HT fast real-time PCR system (Applied Biosystems). The individual performances of the 7 genes are shown in Table 7. The best performing gene in fecal samples from patients with CRC corresponded to PHACTR with 68% sensitivity with a corresponding specificity of 100%.

Table 7: Performance of the individual methylation markers in fecal samples set B

Gene	NDRG4	FoxE1	PHACTR	GATA4	OSMR	SYNE1	SFRP2
cutoff	2	0	100	10	1	3	2
Specificity	100%	94%	100%	100%	88%	100%	100%
Sensitivity for advanced adenoma	0%	0%	10%	10%	20%	10%	10%
Sensitivity for CRC	35%	55%	68%	43%	45%	65%	58%

Performance of FIT in fecal samples (set B)

FIT was evaluated in the same fecal samples. The performance in fecal samples is shown in Table 8.

Table 8: Performance of FIT in fecal samples set B

	FIT
Cutoff (ng/ml)	100
Specificity	100%
Sensitivity for advanced adenoma	10%
Sensitivity for CRC	78%

The FIT obtained a sensitivity of 78% and a corresponding specificity of 100%

Performance of the methylation markers and combinations thereof with or without FIT in fecal samples set B

The performance of combination of 3 methylation markers was investigated with or without FIT. Methylated copies of the genes were quantified in the available stool samples by real-time MSP on a 7900HT fast real-time PCR system (Applied Biosystems). Table 9 shows the results and lists the cut-off (copies) applied.

Table 9: Performance of the 3 methylation marker combinations in set B

FIT (ng/ml)	100	100	100	100				
NDRG4 (copies)	2	2		2	2	2		2
FOXE1 (copies)	0	0	0		0	0	0	
PHACTR (copies)	100		100	100	100		100	100
Spec (n=17)	94%	94%	94%	100%	94%	94%	94%	100%
Sens adv adenoma (n=10)	20%	20%	20%	20%	10%	0%	10%	10%
Sens CRC (n=40)	95%	88%	95%	95%	70%	58%	70%	68%

Use of FIT as first line screening and methylation as a second line confirmation assay

A simulation was made wherein the FIT test would be used a screening test and whereby a low cutoff of 10 ng/ml would be used to maximize the sensitivity. For samples with more than 10 ng/ml hemoglobin and less than 200 ng/ml the methylation test can be used to increase the specificity for this subgroup. Samples are scored as positive if the FIT value is higher than 200 ng/ml or if one of the methylation markers is positive.

Table 10 shows the sensitivity and specificity of the FIT test as a first line test, as well as the overall sensitivity and specificity of the combination of FIT as first line and confirmation with "FIT > 200 OR a positive result on a methylation panel consisting of three genes".

- 5 Results for panel A when only applying the combination of FIT and methylation markers to samples having more than > 10 and less than 200 ng/ml hemoglobin.

Total number of tested with FIT = 44	Number of patients to be tested with the methylation panel = 5	FOXE1 (copies)	0
		NDRG4 (copies)	0
		PHACTR (copies)	50
		Spec (n=21)	95%
		Sens (n=23)	83%

Results for panel B when only applying the combination of FIT and methylation markers to samples having more than > 10 and less than 200 ng/ml hemoglobin.

Total number of tested with FIT = 67	Number of patients to be tested with the methylation panel = 12	FOXE1 (copies)	0
		NDRG4 (copies)	0
		PHACTR (copies)	50
		Spec (n=17)	94%
		Sens adv adenoma (n=10)	20%
		Sens CRC (n=40)	88%

Example 2

FIT and methylation testing on partial stool samples

- 15 In Example 1 homogenates of whole stool sample material were investigated. In this example, the inventor evaluated whether sufficient DNA material could be subtracted from partial stool samples allowing subsequent methylation analysis.

Sample collection and nucleic acid isolation

82 historical stool samples, collected between 2003 and 2008, were available for the present study. The samples were frozen down at the time of collection without addition of stabilizing buffer and stored at -20°C until further use.

5 In this study only a portion of the stool sample ($\approx 1\text{g}$) was investigated for further methylation testing. First, historical samples were thawed at the storage site and partial samples were taken ($\approx 1\text{g}$) using special designed stool tubes with integrated measuring spoons (Sarstedt). Each sample was then weighted and 2 volumes of stabilizing buffer (Diagn MoI Pathol; Volume 14, Number 3, September 2005) were added. Samples were stored at -
10 80°C until the complete sample set was ready for transfer to the processing site.

DNA from these samples was prepared using the QiaAmp DNA stool minikit (Qiagen) following the same procedure as detailed in example 1, sample set A. Adapted volumes were used for starting material and elution: 3 DNA isolations were done per stool sample, processing 250 μl of homogenized stool material each, and elute in 75 μl of buffer AE.
15 At the end, eluates of the same sample were pooled and DNA was quantified using the Picogreen® dsDNA quantitation kit (Molecular Probes, #P7589) following the manufacturer's directions.

DNA modification and amplification

Samples were subjected to bisulfite modification using a commercially available kit
20 (i.e. Zymo, #D5002) as discussed in example 1. Again, input material and elution volume were slightly adapted for this study: up to 2 μg of input DNA was used and elution was done in 30 μl Tris-HCl (1mM, pH 8.0); samples were stored at -80°C, until further processing.

Real-time MSP was performed as set out in example 1. DNA methylation patterns of the PHACTR3 gene were determined by chemical modification of unmethylated but not the
25 methylated cytosines to uracil and subsequent PCR using primers specific for the methylated version, sequence details are provided in Table 1.

Results Methylation status for patients was studied in DNA extracted from partial stool samples derived from historical faecal collections. Average yield of DNA was 7 μg (ranging from 0.3 to 27 μg , SD 5 μg) resulting in sufficient DNA material for subsequent

bisulfite modification and real-time MSP procedure. Methylated copies of the PHACTR3 genes were quantified in the available stool portions. Performance of this methylation marker and combination with or without FIT were comparable with the above reported data from the prospectively collected whole stool sample set.

5 The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims. Moreover, all embodiments described herein are considered to be broadly
10 applicable and combinable with any and all other consistent embodiments, as appropriate.

CLAIMS

I claim:

1. A method of processing a freshly-defecated fecal sample from a human subject without freezing, the method comprising:
 - a) preparing a pair of fecal portions from the fecal sample, wherein the fecal sample is collected at home and partitioned into a pair of fecal portions by the subject by a process comprising:
 - i) defecating directly into a sealable vessel to produce the fecal sample;
 - ii) removing a portion of the fecal sample to produce a removed portion and a remaining portion, wherein the removing comprises using a collection device provided with a sealable container to remove the removed portion to the sealable container, and wherein the sealable container contains a buffer solution that prevents denaturation or degradation of blood proteins;
 - iii) sealing the sealable container; and
 - iv) combining the remaining portion of the fecal sample in the sealable vessel with a stabilizing buffer that maintains nucleic acid integrity, and sealing the sealable vessel;
 - and
 - b) shipping or delivering the sealed sealable container containing the removed portion of the fecal sample and the buffer solution and the sealed sealable vessel containing the remaining portion of the fecal sample and the stabilizing buffer to a medical facility or laboratory.
2. A method of processing a fecal sample, the method comprising:
 - a) obtaining a pair of fecal portions from a fecal sample collected from a human subject, the pair of portions comprising:
 - i) a sealed sealable container containing a removed portion of a fecal sample and a buffer solution that prevents denaturation or degradation of

blood proteins; and

ii) a sealed sealable vessel containing a remaining portion of a fecal sample and a stabilizing buffer that maintains nucleic acid integrity,

wherein the pair of fecal portions are prepared by processing a freshly-defecated fecal sample by the method of claim 1;

b) immunochemically testing the removed portion of the fecal sample using anti-hemoglobin antibodies to determine an amount of hemoglobin present in the removed portion; and

c) detecting human nucleic acid from the remaining portion of the fecal sample using polymerase chain reaction (PCR) with a fluorophore-labeled probe.

3. The method of claim 2, wherein the human nucleic acid comprises human RNA, and wherein the detecting comprises measuring an amount of at least one human RNA by reverse-transcription PCR (RT-PCR).
4. The method of claim 2, wherein determining an amount of hemoglobin present in the removed portion comprises testing the removed portion for a concentration of hemoglobin, wherein a concentration of hemoglobin in the removed portion is indicative of a presence of blood in the removed portion of the fecal sample.
5. The method of claim 4, wherein the removed portion of the fecal sample is considered positive for the presence of blood when the concentration of hemoglobin detected in the removed portion is between 5 ng/ml and 250 ng/ml.
6. The method of claim 4, wherein the removed portion of the fecal sample is considered positive for the presence of blood when the concentration of hemoglobin detected in the removed portion is between 5 ng/ml and 50 ng/ml.
7. The method of claim 4, wherein the removed portion of the fecal sample is considered positive for the presence of blood when the concentration of hemoglobin detected in the removed portion is between 5 ng/ml and 20 ng/ml.

8. The method of claim 4, wherein the removed portion of the fecal sample is considered positive for the presence of blood when the concentration of hemoglobin detected in the removed portion is between 10 ng/ml and 200 ng/ml.
9. The method of claim 4, wherein the removed portion of the fecal sample is considered positive for the presence of blood when the concentration of hemoglobin detected in the removed portion is between 5 ng/ml and 150 ng/ml.
10. The method of claim 4, wherein the removed portion of the fecal sample is considered positive for the presence of blood when the concentration of hemoglobin detected in the removed portion is greater than a predetermined threshold concentration.
11. The method of claim 10, wherein the threshold concentration is at least 5 ng/ml.
12. The method of claim 10, wherein the threshold concentration is at least 10 ng/ml.
13. The method of claim 10, wherein the threshold concentration is at least 20 ng/ml.
14. The method of claim 10, wherein the threshold concentration is at least 50 ng/ml.
15. The method of claim 10, wherein the threshold concentration is at least 100 ng/ml.
16. The method of claim 10, wherein the threshold concentration is at least 150 ng/ml.
17. The method of claim 10, wherein the threshold concentration is at least 200 ng/ml.
18. The method of claim 10, wherein the threshold concentration is at least 250 ng/ml.
19. A kit for collection of a pair of fecal portions from a fecal sample at home by a human subject, comprising:
 - a) a sealable vessel for collection of the fecal sample, the sealable vessel configured for a human subject to directly defecate into the sealable vessel;
 - b) a sealable container for receiving a removed portion of the fecal

- sample, the sealable container containing therein a buffer solution that inhibits denaturation or degradation of blood proteins; and
- c) a stabilizing buffer for maintaining nucleic acid integrity.
20. The kit of claim 19, wherein the stabilizing buffer has a volume of at least 250 ml.
21. The kit of claim 19, further comprising a collection device adapted to remove a portion of the fecal sample to produce the removed portion, and to transfer the removed portion to the sealable container.
22. The kit of claim 21, wherein the collection device is an integral part of the sealable container.
23. The kit of claim 22, wherein the collection device is adapted to remove a portion of 1 gram or less from the fecal sample.
24. The kit of claim 22, wherein the collection device is adapted to deliver 1 gram or less of the fecal sample into the sealable container.
25. The kit of claim 19, wherein the sealable vessel has a volume suitable for containing:
- a remaining portion of the fecal sample; and
 - a volume of the stabilizing buffer that is at least 7 times the volume of the remaining portion of the fecal sample.
26. The kit of claim 19, wherein the sealable vessel is sealed and contains a remaining portion of a fecal sample from a human subject and the stabilizing buffer, and wherein the sealable container contains the removed portion of the fecal sample and the buffer solution.
27. The kit of claim 26, wherein the sealable vessel contains a volume of the stabilizing buffer that is at least 7 times the volume of the remaining portion of the fecal sample contained in the sealable vessel.

28. The kit of claim 26, wherein the sealable vessel contains a volume of at least 250 ml of the stabilizing buffer.
29. The kit of claim 25, wherein the sealable container contains a removed portion of 1 gram or less of the fecal sample.
30. A method of screening a group of human subjects for colorectal malignancies and/or pre-malignancies, comprising:
 - a) providing each member of the group of human subjects with a kit for collection of a pair of fecal portions from a fecal sample at home by a human subject, the kit comprising:
 - i) a sealable vessel for collection of the fecal sample, the sealable vessel configured for a human subject to directly defecate into the sealable vessel;
 - ii) a sealable container for receiving a removed portion of the fecal sample, containing therein a buffer solution that inhibits denaturation or degradation of blood proteins; and
 - iii) a stabilizing buffer for maintaining nucleic acid integrity,wherein the group of subjects are each asymptomatic for colorectal malignancies and/or pre-malignancies; and
wherein a plurality of members of the group of human subjects each prepare a pair of fecal portions by processing a freshly-defecated fecal sample by the method of claim 1, the pair of portions comprising:
 - (1) a sealed sealable container containing the removed portion of the fecal sample and the buffer solution that prevents denaturation or degradation of blood proteins; and
 - (2) a sealed sealable vessel containing the remaining portion of the fecal sample and the stabilizing buffer for maintaining nucleic acid integrity;
 - b) receiving pairs of fecal portions from the plurality of members of the group of human subjects; and

- c) for each of a plurality of the pairs of fecal portions received in b):
 - i) immunochemically testing the removed portion of the fecal sample using anti-hemoglobin antibodies to determine an amount of hemoglobin present in the removed portion; and
 - ii) detecting human nucleic acid from the remaining portion of the fecal sample using polymerase chain reaction (PCR) with a fluorophore-labeled probe.

ABSTRACT

Methods and kits directed to processing a fresh fecal sample from a human subject by a process comprising removing a portion of a collected fecal sample and adding the removed portion of the sample to a buffer that prevents denaturation or degradation of blood proteins, and stabilizing the remaining portion of the fecal sample with a stabilizing buffer that maintains nucleic acid integrity.

**CERTIFICATION AND REQUEST FOR PRIORITIZED EXAMINATION
UNDER 37 CFR 1.102(e) (Page 1 of 1)**

First Named Inventor:	LOUWAGIE	Nonprovisional Application Number (if known):	
Title of Invention:	FECAL SAMPLE PROCESSING AND ANALYSIS COMPRISING DETECTION OF BLOOD		

APPLICANT HEREBY CERTIFIES THE FOLLOWING AND REQUESTS PRIORITIZED EXAMINATION FOR THE ABOVE-IDENTIFIED APPLICATION.

1. The processing fee set forth in 37 CFR 1.17(i), the prioritized examination fee set forth in 37 CFR 1.17(c), and if not already paid, the publication fee set forth in 37 CFR 1.18(d) have been filed with the request. The basic filing fee, search fee, examination fee, and any required excess claims and application size fees are filed with the request or have been already been paid.
2. The application contains or is amended to contain no more than four independent claims and no more than thirty total claims, and no multiple dependent claims.
3. The applicable box is checked below:

I. ☒ Original Application (Track One) - Prioritized Examination under § 1.102(e)(1)

- i. (a) The application is an original nonprovisional utility application filed under 35 U.S.C. 111(a). This certification and request is being filed with the utility application via EFS-Web.
---OR---
(b) The application is an original nonprovisional plant application filed under 35 U.S.C. 111(a). This certification and request is being filed with the plant application in paper.
- ii. An executed oath or declaration under 37 CFR 1.63 is filed with the application.

II. ☐ Request for Continued Examination - Prioritized Examination under § 1.102(e)(2)

- i. A request for continued examination has been filed with, or prior to, this form.
- ii. If the application is a utility application, this certification and request is being filed via EFS-Web.
- iii. The application is an original nonprovisional utility application filed under 35 U.S.C. 111(a), or is a national stage entry under 35 U.S.C. 371.
- iv. This certification and request is being filed prior to the mailing of a first Office action responsive to the request for continued examination.
- v. No prior request for continued examination has been granted prioritized examination status under 37 CFR 1.102(e)(2).

Signature	/Mary Ann D. Brow/	Date	2024-10-17
Name (Print/Typed)	Mary Ann D. Brow	Practitioner Registration Number	42363
Note: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required in accordance with 37 CFR 1.33 and 11.18. Please see 37 CFR 1.4(d) for the form of the signature. If necessary, submit multiple forms for more than one signature, see below*.			
☒ *Total of <u>1</u> forms are submitted.			

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	18/539,214
				Filing Date	13-Dec-2023
				First Named Inventor	JOOST LOUWAGIE
				Art Unit	
				Examiner Name	
Sheet	1	of	11	Attorney Docket Number	EXCTD-35239.310

U.S. PATENTS					
Exami ner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Issue or Publication Date YYYY-MM-DD	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		4437975	1984-03-20	GILLESPIE et al.	
		4445235	1984-05-01	SLOVER et al.	
		4582811	1986-04-15	PUCCI et al.	
		4683197	1987-07-28	GALLATI	
		4859610	1989-08-22	MAGGIO	
		4889818	1989-12-26	GELFAND et al.	
		5137806	1992-08-11	LEMAISTRE et al.	
		5196167	1993-03-23	GUADAGNO et al.	
		5198365	1993-03-30	GROW et al.	
		5527676	1996-06-18	VOGELSTEIN et al.	
		5741650	1998-04-21	LAPIDUS et al.	
		5952178	1999-09-14	LAPIDUS et al.	
		6410276	2002-06-25	BURG et al.	
		6761702	2004-07-13	SMITH	
		7195878	2007-03-27	CLEATOR	
		7288413	2007-10-30	GOULDEN	
		7371527	2008-05-13	BAYLIN et al.	
		8969046	2015-05-03	VAN ENGELAND et al.	
		9163278	2015-10-20	BRUINSMA et al.	
		9891223	2019-02-13	BEAULIEU et al.	
		11634781	2023-04-25	LOUWAGIE	
		11970746	2024-04-30	LOUWAGIE	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	18/539,214
				Filing Date	13-Dec-2023
				First Named Inventor	JOOST LOUWAGIE
				Art Unit	
				Examiner Name	
Sheet	2	of	11	Attorney Docket Number	EXCTD-35239.310

U.S. PUBLISHED PATENT APPLICATIONS					
Exami ner Initials*	Cite No. ³	Document Number Number-Kind Code ⁴ (if known)	Issue or Publication Date YYYY-MM-DD	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		20020096469	2002-07-25	FAULKNER	
		20020187476	2002-12-12	KOROULIS et al.	
		20030086869	2003-05-08	STALLINGS	
		20030096244	2003-05-22	RABELLO et al.	
		20040019298	2004-01-29	ZHOU et al.	
		20040091881	2004-05-13	OLEK et al.	
		20050064401	2005-03-24	OLEK et al.	
		20050075543	2005-04-07	CALABRESE	
		20050244836	2005-11-03	TSANG	
		20060084054	2006-04-20	ALSOBROOK et al.	
		20060188939	2006-08-24	GAO	
		20060210448	2006-09-21	WANG et al.	
		20060216714	2006-09-28	KANAOKA	
		20060216830	2006-09-28	KIKUIRI	
		20070017015	2007-01-25	FINELL	
		20070072214	2007-03-29	GARVIN	
		20080097238	2008-04-24	LOKTIONOV et al.	
		20080124714	2008-05-29	SHUBER et al.	
		20080221056	2008-09-11	BAYLIN et al.	
		20080227208	2008-09-18	YEE et al.	
		20090004058	2009-01-01	LIANG et al.	
		20100136572	2010-06-03	ATAMAN-ONAL et al.	
		20120164238	2012-06-28	LOUWAGIE	
		20120164238	2012-06-28	JOOST	
		20160194723	2016-07-07	LOUWAGIE	
		20160194723	2016-07-07	LOUWAGIE	
		20230048152	2023-02-16	LOUWAGIE	

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	18/539,214
				Filing Date	13-Dec-2023
				First Named Inventor	JOOST LOUWAGIE
				Art Unit	
				Examiner Name	
Sheet	3	of	11	Attorney Docket Number	EXCTD-35239.310

FOREIGN PATENT DOCUMENTS						
Exami ner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date YYYY-MM-DD	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translati on ⁸
		Country Code ⁵ Number ⁶ Kind Code ⁷ (if known)				
		EP 0032782	1981-07-29	KOMMANDIITTIYHTIO FINNPIPETTE		
		EP 0308227	1989-03-22	SMITHKLINE DIAGNOSTICS, INC.		
		EP 0817968	1998-01-14	EXACT SCIENCES CORPORATION		
		EP 1366715	2003-12-03	SENTINEL CH. S.r.L		
		FR 2919065	2009-01-23	BIOMERIEUX		
		WO 1990/06995	1990-06-28	SISKA DIAGNOSITCS, INC.		
		WO 1997/25925	1997-07-24	HULIOT PLASTICS INDUSTRIES et al.		
		WO 1997/46705	1997-12-11	THE JOHNS HOPKINS SCHOOL OF MEDICINE		
		WO 2000/050640	2000-08-31	EXACT LABORATORIES, INC.		
		WO 2003/076594	2003-09-18	THE JOHNS HOPKINS UNIVERSITY		
		WO 2004/067726	2004-08-12	KECK GRADUATE INSTITUTE		
		WO 2004/083399	2004-09-30	THE JOHNS HOPKINS UNIVERSITY		
		WO 2004/0927209	2004-10-28	KIETURAKIS & KARCZEWSKI		
		WO 2005/014154	2005-02-17	LOOTS LIMITED		
		WO 2005/014154	2005-02-17	LOOTS LIMITED		
		WO 2005/017207	2005-02-24	CASE WESTERN RESERVE UNIVERSITY		
		WO 2005/113769	2005-12-01	EXACT SCIENCES CORPORATION		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	18/539,214
				Filing Date	13-Dec-2023
				First Named Inventor	JOOST LOUWAGIE
				Art Unit	
				Examiner Name	
Sheet	4	of	11	Attorney Docket Number	EXCTD-35239.310

FOREIGN PATENT DOCUMENTS						
		WO 2006/113671	2006-10-26	ONCOMETHYLOME SCIENCES SA		
		WO 2008/010975	2008-01-24	THE JOHNS HOPKINS UNIVERSITY		
		WO 2008/084219	2008-07-17	ONCOMETHYLOME SCIENCES SA		
		WO 2008/100913	2008-08-21	THE JOHNS HOPKINS UNIVERSITY		
		WO 2008/102002	2008-08-28	RIKSHOSPITALET RADIUMHOSPITALE		
		WO 2009/102788	2009-08-20	MAYO FONDATION FOR MEDICAL EDUCATION AND RESEARCH		

NONPATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	Translation ⁶
		ABBASZADEGAN et al., Stool-based DNA testing, a new noninvasive method for colorectal cancer screening, the first report from Iran. World J Gastroenterol. 2007 Mar 14;13(10):1528-33	
		AHLQUIST et al., A Stool Collection Device: The First Step in Occult Blood Testing, Annals of Internal Medicine, 108(4):609-612 (1988)	
		AHLQUIST et al., Cologuard Primed to Change Landscape of CRC Screening", Mayo Clinic Clinical Updates, http://www.mayoclinic.org/medical-professionals/clinical-updates/digestivediseases/cologuard-primed-to-change-landscape-of-crc-screening , Pages 1-4, 12/03/2014.	
		AHLQUIST et al., Colorectal Cancer Screening by Detection of Altered Human DNA in Stool: Feasibility of a Multitarget Assay Panel, Gastroenterology, 119(5):1219-1227 (2000)	
		AHLQUIST et al., Molecular Stool Screening for Colorectal Cancer. Using DNA Markers May Be Beneficial, But Large Scale Evaluation is Needed. BMJ, 29;321:254-5 (2000)	
		AHLQUIST et al., Stool DNA and Occult Blood Testing for Screen Detection of Colorectal Neoplasia. Ann Intern Med.,149(7):441-450, W81 (2008)	
		AHMED et al., Transcriptomic Molecular Markers for Screening Human Colon Cancer in Stool and Tissue, Cancer Genomics and Proteomics 4:1-20 (2007)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	18/539,214
				Filing Date	13-Dec-2023
				First Named Inventor	JOOST LOUWAGIE
				Art Unit	
				Examiner Name	
Sheet	5	of	11	Attorney Docket Number	EXCTD-35239.310

NONPATENT LITERATURE DOCUMENTS			
		AUERKARI, Methylation of tumor suppressor genes p16(INK4a), p27(Kip1) and E-cadherin in carcinogenesis. Oral Oncol. 2006 Jan;42(1):5-13	
		BEEKER et al., Colorectal Cancer Screening in Older Men and Women: Qualitative Research Findings and Implications for Interventions. J Comm Health 2000; 25(3):263-278	
		BOYNTON et al., DNA Integrity as a Potential Marker for Stool-based Detection of Colorectal Cancer, Clinical Chemistry, 49(7):1058-1065 (2003)	
		CHEN et al., Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst. 2005 Aug 3;97(15):1124-32	
		Cologuard® webpage, retrieved from https://www.exactsciences.com/cancer-testing/cologuard-stool-test , 2024, 7 pages	
		Cologuard® Physician Brochure, date unknown, 12 pages	
		CONROY et al., Exact Sciences Completes 40,000 Cologuard Tests During First Quarter 2016, Exact Sciences Latest News, Pages 1-10, 05/03/2016.	
		Curriculum Vitae of Duncan H. Whitney, Ph.D., filed January 11, 2024, 10 pages	
		Declaration of Brendan T. Jones, dated January 11, 2024, 11 pages	
		Declaration of Brendan T. Jones, dated August 20, 2024, 17 pages	
		Declaration of Duncan Whitney, Ph.D., dated January 10, 2024, 186 pages	
		Declaration of Duncan Whitney, Ph.D., dated August 20, 2024, 225 pages	
		Declaration of Mr. Anthony P. Shuber, MS, Reexam Application 90/015,237, filed May 22, 2023, 63 pages	
		Decision Granting Institution of Inter Partes Review for IPR2024-00459, Patent 11,634,781, mailed July 26, 2024, 34 pages	
		DERKS et al., Promoter Methylation Precedes Chromosomal Alterations in Colorectal Cancer Development, Abstract, Cell Oncol, 28(5-6):247-257 (2006), retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618222/ , on January 9, 2024, 2 pages	
		DERKS et al., Promoter Methylation Precedes Chromosomal Alterations in Colorectal Cancer Development, Cellular Oncology, 28(5-6):247-257 (2006)	
		DOLLINGER et al., Abstract S1134, Screening for Colorectal Cancer: A Blinded Multicenter Phase II Diagnostic Study for Validation of a DNA Based Stool Test (Genefec2®). Gastroenterology. 2008;134(4)(Suppl. 1):A185	
		EGUCHI et al., Mutations of the P53 Gene in Stool of Patients with Resectable Colorectal Cancer, Cancer, 77(8):1707-1710 (1996)	
		Ex Parte Reexamination Certificate for US Patent 11,637,781, issued December 4, 2023, 2 pages	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	18/539,214
				Filing Date	13-Dec-2023
				First Named Inventor	JOOST LOUWAGIE
				Art Unit	
				Examiner Name	
Sheet	6	of	11	Attorney Docket Number	EXCTD-35239.310

NONPATENT LITERATURE DOCUMENTS					
		Exact Sciences and Mount Sinai School of Medicine, Stool DNA Testing For Colon Cancer, Press Release issued December 13, 2006, retrieved from https://www.sciencedaily.com/releases/2006/12/061213104115.htm# , on January 9, 2024, 3 pages			
		EXACT SCIENCES, Cologuard(TM) sDNA-based Colorectal Cancer Screening Test - Instructions for Use, Pages 1-71, 2013.			
		EXACT SCIENCES CORPORATION, Cologuard™ sDNA-based Colorectal Cancer Screening Test - Instructions for Use, 2013, 85 pages			
		EXACT SCIENCES, Cologuard™ Patient Guide, 2014, 34 pages			
		EXACT SCIENCES, Cologuard Patents 2024, retrieved from https://www.exactsciences.com/patents-and-trademarks , retrieved August 9, 2024, 4 pages			
		EXACT SCIENCES, Cologuard Patents 2014, retrieved from https://web.archive.org/web/20141206015245/http://www.exactsciences.com:80/patents-and-trademarks , retrieved on August 9, 2024, 4 pages			
		GUITTET et al., Comparison of a Guaiac Based and an Immunochemical Faecal Occult Blood Test In Screening For Colorectal Cancer In A General Average Risk Population, Gut, 56:210-214 (2007)			
		HAMMER, Human hybrids. Sci Am. 2013 May;308(5):66-71			
		HARDISON, Correspondence:Stool DNA: A Viable Option for Colorectal Cancer Screening; Gastroenterology, Volume 129, Issue 6p 2128-2129 December 2005			
		HIRATA et al., Usefulness of Fecal Lactoferrin and Hemoglobin in Diagnosis of Colorectal Diseases, World Journal of Gastroenterology, 14;13(10):1569-74 (2007)			
		HOEPFFNER et al., Comparative evaluation of a new bedside faecal occult blood test in a prospective multicentre study. Aliment Pharmacol Ther. 2006 Jan 1;23(1):145-54			
		IMPERIALE et al., Fecal DNA Versus Fecal Occult Blood for Colorectal-Cancer Screening in an Average-Risk Population, New England Journal of Medicine, 351(26):2704-2714 (2004)			
		IMPERIALE et al., Multitarget Stool DNA Testing for Colorectal-Cancer Screening. NEJM 2014 Apr 3;370(14):1287-97			
		International Preliminary Report on Patentability for PCT/GB2010/000180, mailed August 9, 2011, 20 pages			
		ITZKOWITZ et al., Improved Fecal DNA Test for Colorectal Cancer Screening, Clinical Gastroenterology and Hepatology, 5:111-117 (2007)			
		ITZKOWITZ et al., A Simplified, Noninvasive Stool DNA Test for Colorectal Cancer Detection, American Journal of Gastroenterology, 103:2862-2870 (2008)			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	18/539,214
				Filing Date	13-Dec-2023
				First Named Inventor	JOOST LOUWAGIE
				Art Unit	
				Examiner Name	
Sheet	7	of	11	Attorney Docket Number	EXCTD-35239.310

NONPATENT LITERATURE DOCUMENTS					
		ITZKOWITZ et al., T1098 Improved Non-Invasive Stool DNA (SDNA) Test to Screen for Colorectal Cancer (CRC): Validation of High Sensitivity and Specificity, Gastroenterology Vol. 134 Issue 4 Supplement A-483; Abstract Published in issue: April, 2008			
		JESSUP et al., Diagnosing Colorectal Carcinoma: Clinical and Molecular Approaches, A Cancer Journal for Clinicians, 47(2):70-92 (1997)			
		JIANG et al., T1102 Detection of Colorectal Neoplasia By Stool DNA Testing: High Discrimination with Multi-Marker Quantitation Gastroenterology Vol. 134 Issue 4 Supplement A-484 Published in issue: April, 2008			
		KAHI et al., Screening, Surveillance, and Primary Prevention for Colorectal Cancer: A Review of the Recent Literature, Gastroenterology, 135:380-399 (2008)			
		KANAOKA et al., Potential Usefulness of Detecting Cyclooxygenase 2 Messenger RNA in Feces for Colorectal Cancer Screening, Gastroenterology, 127:422-427 (2004)			
		KARL et al., Improved diagnosis of colorectal cancer using a combination of fecal occult blood and novel fecal protein markers. Clin Gastroenterol Hepatol. 2008 Oct;6(10):1122-8			
		KIM et al., Noninvasive Molecular Biomarkers for the Detection of Colorectal Cancer. BMB Rep. 2008 Oct 31;41(10):685-92			
		KUTZNER et al., Non-invasive detection of colorectal tumours by the combined application of molecular diagnosis and the faecal occult blood test. Cancer Lett. 2005 Nov 8;229(1):33-41			
		LAIRD, The power and the promise of DNA methylation markers. Nat Rev Cancer. 2003 Apr;3(4):253-66			
		LENHARD et al., Analysis of promoter methylation in stool: A Novel method for the detection of colorectal cancer, Clinical Gastroenterology and Hepatology, 3(2):P142-149 (2005), retrieved from https://www.cghjournal.org/article/S1542-3565(04)00624-X/fulltext , on January 9, 2024, 27 pages			
		LENHARD et al., Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer. Clin Gastroenterol Hepatol. 2005 Feb;3(2):142-9			
		LEUNG et al., Detection of Hypermethylated DNA or Cyclooxygenase-2 Messenger RNA in Fecal Samples of Patients with Colorectal Cancer or Polyps. Am J Gastroenterol 2007;102:1070-6			
		LEVI et al., A quantitative immunochemical faecal occult blood test is more efficient for detecting significant colorectal neoplasia than a sensitive guaiac test. Aliment Pharmacol Ther. 2006 May 1;23(9):1359-64			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	18/539,214
				Filing Date	13-Dec-2023
				First Named Inventor	JOOST LOUWAGIE
				Art Unit	
				Examiner Name	
Sheet	8	of	11	Attorney Docket Number	EXCTD-35239.310

NONPATENT LITERATURE DOCUMENTS			
		LEVIN et al., Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, a Joint Guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology, Gastroenterology, 134:1570-1595 (2008)	
		LI et al., MethPrimer: Designing Primers for Methylation PCRs, Bioinformatics, 18(11):14271431 (2002)	
		LinkedIn Page of Joost Louwagie, retrieved from https://www.linkedin.com/in/joost-louwagie/?originalSubdomain=ch , on January 10, 2024, 3 pages	
		MAHON, Prevention and Screening of Gastrointestinal Cancers, Seminars in Oncology Nursing, 25(1):15-31 (2009)	
		MATSUMURA et al., Non-Invasive Detection of Malignancy by Identification of Unusual CD44 Gene Activity in Exfoliated Cancer Cells, BMJ, 308:619-624 (1994)	
		MATSUMURA et al., Significance of CD44 Gene Products for Cancer Diagnosis and Disease Evaluation, Lancet, 340:1053-1058 (1992)	
		MELVIN and BROOKE, Laboratory Procedures for the Diagnosis of Intestinal Parasites, Third Edition, 1982, published by U.S. Department of Health and Human Services, Centers for Disease Control, Atlanta, Georgia, 284 pages	
		MULDER et al., Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer. Eur J Gastroenterol Hepatol. 2007 Oct;19(10):878-82	
		MÜLLER et al., Methylation Changes in Faecal DNA: A Marker for Colorectal Cancer Screening? Lancet, 63:1283-1285 (2004)	
		NECHVATAL et al., Fecal Collection, Ambient Preservation, and DNA Extraction for PCR Amplification of Bacterial And Human Markers from Human Feces, Journal of Microbiological Methods, 72(2):124-32 (2008)	
		NISHIKAWA et al., A Simple Method Of Detecting K-Ras Point Mutations in Stool Samples for Colorectal Cancer Screening Using One-Step Polymerase Chain Reaction/Restriction Fragment Length Polymorphism Analysis, Clinica Chimica Acta, 318:107-112 (2002)	
		OHLSSON et al., Biomarker selection for detection of occult tumour cells in lymph nodes of colorectal cancer patients using real-time quantitative RT-PCR. Br J Cancer. 2006 Jul 17;95(2):218-25	
		OLSON et al., DNA Stabilization is Critical for Maximizing Performance of Fecal DNA-Based Colorectal Cancer Tests. Diagn Mol Pathol 2005;14:183-191	
		OORT et al., S1117 Faecal Occult Blood Tests: Immunological Superior to Guaiac Based? Gastroenterology Vol. 134 Issue 4 Supplement A-181 Published in issue: April, 2008	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	18/539,214
				Filing Date	13-Dec-2023
				First Named Inventor	JOOST LOUWAGIE
				Art Unit	
				Examiner Name	
Sheet	9	of	11	Attorney Docket Number	EXCTD-35239.310

NONPATENT LITERATURE DOCUMENTS			
		OSTROW, Tests for Fecal Occult Blood, Chapter 98 in Clinical Methods: The History, Physical, and Laboratory Examinations. Third Edition, eds. Walker et al, Boston: Butterworths, 3 pages (1990)	
		Patent Owner's Preliminary Response, in IPR2024-00459 of U.S. Patent 11,634,781, filed April 30, 2024, 71 pages	
		Patent Owner's Sur-Reply, in IPR2024-00459 of U.S. Patent 11,634,781, filed June 10, 2024, 13 pages	
		Petition for Inter Parties Review of U.S. Patent 11,634,781, filed January 11, 2024, 87 pages	
		Petition for Inter Parties Review of U.S. Patent 11,970,746, filed August 20, 2024, 90 pages	
		Petitioner's Reply to Patent Owner's Preliminary Reply, in IPR2024-00459 of U.S. Patent 11,634,781, filed May 30, 2024, 13 pages	
		Provisional Patent Application Transmittal for U.S. Provisional Patent Application US61/149,581, dated February 3, 2009, 3 pages	
		Recorded Assignment of US Patent No. 11,634,781 dated April 25, 2017, 5 pages	
		REIN et al., Identifying 5-methylcytosine and related modifications in DNA genomes. Nucleic Acids Res. 1998 May 15;26(10):2255-64	
		RENNERT et al., Detecting K-Ras Mutations in Stool from Fecal Occult Blood Test Cards in Multiphasic Screening for Colorectal Cancer, Cancer Letters, 253:258-264 (2007)	
		Request for Ex Parte Reexamination of U.S. Patent 11,634,781, filed May 22, 2023, 286 pages	
		Response to Non-Final Office Action for U.S. Patent Application 18/179,945, dated October 6, 2023, 11 pages	
		Response to Final Office Action for U.S. Patent Application 14/145,082, dated July 31, 2015, 123 pages	
		SCHROY et la., Patient Persceptions of Stool-Based DNA Testing for Colorectal Cancer Screening. Am J Prev Med 2005;28(2):208-14	
		SCHUEBEL et al., Comparing the DNA Hypermethylome with Gene Mutations in Human Colorectal Cancer, PLoS Genet., 3(9):1709-1723 (2007)	
		SHASTRI et al., Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study. Am J Gastroenterol. 2008 Jun;103(6):1496-504	
		SHEN et al., Integrated Genetic and Epigenetic Analysis Identifies Three Different Subclasses of Colon Cancer. Proc Natl. Acad. Sci. U.S.A., 104(47): 18654-18659 (2007)	
		SIDRANSKY, Identification of ras Oncogene Mutations in the Stool of Patients with Curable Colorectal Tumors, Science, 256:102-105 (1992)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	18/539,214
				Filing Date	13-Dec-2023
				First Named Inventor	JOOST LOUWAGIE
				Art Unit	
				Examiner Name	
Sheet	10	of	11	Attorney Docket Number	EXCTD-35239.310

NONPATENT LITERATURE DOCUMENTS			
		SIMON, Occult Blood Screening for Colorectal Carcinoma: A Critical Review, Gastroenterology, 88:820837 (1985)	
		SOMMER et al., Minimal homology requirements for PCR primers. Nucleic Acids Res. 1989 Aug 25;17(16):6749	
		TAGORE et al. Review Article: The Evolution to Stool DNA Testing for Colorectal Cancer, Aliment Pharmacol. Ther., 19:1225-1233 (2004)	
		TURGEON et al., Fecal DNA-Based Detection of Colorectal Neoplasia. Curr Colorectal Cancer Rep. 2007 Oct;3(4):171-177	
		US Provisional Patent Application US61/149,581, filed February 3, 2009, 59 pages	
		USPTO Final Office Action for US Patent Publication No. US15/010,436 dated October 28, 2016, 15 pages	
		USPTO Nonfinal Office Action for US Patent Publication No. US17/936,335 dated January 11, 2023, 7 pages	
		USPTO Non-Final Office Action for US Patent Application No. US 18/179,945, mailed July 6, 2023, 7 pages	
		USPTO Notice of Intent to Issue Ex Parte Reexamination Certificate for US Patent No. 11,634,781 dated Oct 18, 2023, 5 pages	
		USPTO Order Granting Request for Ex Parte Reexamination of US Patent No. 11,634,781 dated June 29, 2023, 18 pages	
		United States Securities and Exchange Commission, Form 10-K for EXACT SCIENCES CORPORATION, 2023, 151 pages	
		VERNON, Participation in Colorectal Cancer Screening: a Review. J National Cancer Institute 1997 Oct 1; 89(19):1406-22	
		VILKIN et al., Performance Characteristics and Evaluation of an Automated-Developed and Quantitative, Immunochemical Fecal Occult Blood Screening Test, American Journal of Gastroenterology, 100:2519-2525 (2005)	
		VILLA et al., Identification of Subjects at Risk for Colorectal Carcinoma through a Test Based on K-Ras Determination in the Stool, Gastroenterology, 110:1346-1353 (1996)	
		VILLAR-GAREA et al., DNA demethylating agents and chromatin-remodelling drugs: which, how and why? Curr Drug Metab. 2003 Feb;4(1):11-31	
		WHITE et al., Colorectal Cancer: Prevention and Early Diagnosis, Medicine, 35(6):297--301 (2007)	
		WHITNEY et al., Enhanced Retrieval of DNA from Human Fecal Samples Results in Improved Performance of Colorectal Cancer Screening Test, J Mol Diagn. Nov; 6(4): 386-395 (2004)	
		YOUNG et al., New Stool Screening Tests for Colorectal Cancer, Digestion, 76:26-33 (2007)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				<i>Application Number</i>	18/539,214
				<i>Filing Date</i>	13-Dec-2023
				<i>First Named Inventor</i>	JOOST LOUWAGIE
				<i>Art Unit</i>	
				<i>Examiner Name</i>	
Sheet	11	of	11	<i>Attorney Docket Number</i>	EXCTD-35239.310

NONPATENT LITERATURE DOCUMENTS			
		YOUNG, Fecal Immunochemical Tests (FIT) vs. Office-Based Guaiac Fecal Occult Blood Test (FOBT), Practical Gastroenterology 28(6):46-56 (2004)	
		ZOU et al., A Sensitive Method to Quantify Human Long DNA in Stool: Relevance to Colorectal Cancer Screening, Cancer Epidemiol Biomarkers Prev, 15(6):1115-1119 (2007)	
		ZOU et al., Highly Methylated Genes in Colorectal Neoplasia: Implications for Screening, Cancer Epidemiol Biomarkers Prev, 16(12):2686-96 (2007)	
		ZOU et al., T1105 A Sensitive Method to Scan Gene Mutations in Stool: Relevance to Detection of Gastrointestinal Neoplasia Gastroenterology Vol. 134 Issue 4 Supplement A-484 Published in issue: April, 2008	
		ZOU et al., T2034 Stool DNA and Occult Blood for Detection of Colorectal Cancer: Complementary Markers, Gastroenterology Vol. 136 Issue 5 Supplement A-625 Published in issue: May, 2009	
		ZOU et al., High Detection Rates of Colorectal Neoplasia by Stool DNA Testing With a Novel Digital Melt Curve Assay, Gastroenterology 136:459-470 (2009)	
		ZOU et al., T2036 Pan-Detection of Gastrointestinal Neoplasms By Stool DNA Testing: Establishment of Feasibility, Gastroenterology Vol. 136 Issue 5 Supplement A-625 Published in issue: May, 2009	
		ZOU et al., T2037 Quantitative Stool DNA Testing for Detection of Both Colorectal Cancer and Advanced Adenoma, Gastroenterology Vol. 136 Issue 5 Supplement A-625 Published in issue: May, 2009	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				<i>Application Number</i>	18/539,214
				<i>Filing Date</i>	13-Dec-2023
				<i>First Named Inventor</i>	JOOST LOUWAGIE
				<i>Art Unit</i>	
<i>Examiner Name</i>					
Sheet	12	of	11	<i>Attorney Docket Number</i>	EXCTD-35239.310

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

- ☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).
- OR**
- ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).
- ☐ See attached certification statement.
- ☐ The fee set forth in 37 CFR 1.17(p) has been submitted herewith.
- ☒ A certification statement is not submitted herewith.
- ☒ Documents not provided herewith have been previously cited in parent U.S. patent application number 13/147,570 filed on March 12, 2012; 15/010,436, filed on January 29, 2016; 15/634,607 filed on June 27, 2017; and/or 17/936,335 filed on September 28, 2022. In compliance with 37 C.F.R. § 1.98(d), Applicants have not included copies of these documents.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Mary Ann D. Brow/	Date (YYYY-MM-DD)	2024-10-15
Name/Print	Mary Ann D. Brow	Registration Number	42363

PTO Notes regarding this form:

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

³ Applicant's unique citation designation number (optional).

⁴ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

⁵ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁶ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁷ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

⁸ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**



ELECTRONIC ACKNOWLEDGEMENT RECEIPT

APPLICATION #
18/919,170

RECEIPT DATE / TIME
10/17/2024 06:09:31 PM Z ET

ATTORNEY DOCKET #
EXCTD-35239.313

Title of Invention

FECAL SAMPLE PROCESSING AND ANALYSIS COMPRISING DETECTION OF BLOOD

Application Information

APPLICATION TYPE Utility - Nonprovisional Application
 under 35 USC 111(a)

PATENT # -

CONFIRMATION # 9076

FILED BY Stephanie Filandrinos

PATENT CENTER # 67619572

FILING DATE -

CUSTOMER # 173254

FIRST NAMED Joost Louwagie
INVENTOR

CORRESPONDENCE -
ADDRESS

AUTHORIZED BY Mary Ann Brow

Documents

TOTAL DOCUMENTS: 42

DOCUMENT	PAGES	DESCRIPTION	SIZE (KB)
2024-10-17_35239.313_ADS_FINAL.pdf	9	Application Data Sheet	2180 KB
35239-313_SEQUENCE_LISTING.xml	-	Sequence Listing Supp (XML File)	35 KB
2024-10-17_35239.313_439.pdf	2	Internet Communications Authorization	85 KB
2024-10-17_35239.313_Exec_Decl.pdf	1	Oath or Declaration filed	106 KB

Warning: The attached file contains comments or annotations. Comments are not recommended and may cause processing problems with the document.

2024-10-15_35239.313_TRACK1.pdf	2	Track One Request	143 KB
2024-10-17_35239.313_EXEC_POA.pdf	2	Power of Attorney	202 KB
2024-10-17_35239.313_IDS.pdf	13	Information Disclosure Statement (IDS) Form (SB08)	560 KB
Warning: The attached file contains comments or annotations. Comments are not recommended and may cause processing problems with the document. This is not a USPTO supplied IDS fillable form. Data in the form cannot be automatically loaded to other USPTO systems.			
2024-07-26_35239.5511_Decision on IPR.pdf	34	Non Patent Literature	2538 KB
2024-10-15_35239.313_APPLICATION.pdf	59	-	1959 KB
2024-10-15_35239.313_APPLICATION-SPEC.pdf	(1-52) 52	Specification	1865 KB
2024-10-15_35239.313_APPLICATION-CLM.pdf	(53-58) 6	Claims	188 KB
2024-10-15_35239.313_APPLICATION-ABST.pdf	(59-59) 1	Abstract	149 KB
ZOU_T1105_2008_NPL.pdf	1	Non Patent Literature	168 KB
ZOU_T2034_2009_NPL.pdf	1	Non Patent Literature	185 KB
ZOU_T2036_2009_NPL.pdf	1	Non Patent Literature	186 KB
HARDISON_2005_NPL.pdf	2	Non Patent Literature	149 KB
ZOU_T2037_2009_NPL.pdf	2	Non Patent Literature	329 KB
WHITNEY_2004_NPL.pdf	10	Non Patent Literature	1365 KB
ITZKOWITZ_T1098_2008_NPL.pdf	1	Non Patent Literature	177 KB
JIANG_T1102_2008_NPL.pdf	1	Non Patent Literature	168 KB
DOLLINGER_2008_NPL.pdf	1	Non Patent Literature	153 KB

OORT_2008_NPL.pdf	1	Non Patent Literature	134 KB
ZOU_GASTRO_2009_NPL.pdf	12	Non Patent Literature	1183 KB
1083_JONES DECLARATION_NPL.pdf	17	Non Patent Literature	260 KB
1080_COLOGUARD PHYSICIAN BROCHURE_NPL.pdf	12	Non Patent Literature	668 KB
1079_EXACT SCIENCES COLOGUARD WEB PAGE_NPL.pdf	7	Non Patent Literature	912 KB
1081_COLOGUARD INSTRUCTIONS FOR USE_NPL.pdf	85	Non Patent Literature	2986 KB
1077_IMPERIALE 2014_NPL.pdf	11	Non Patent Literature	1433 KB

Warning: The PDF file contains multiple layers and must be flattened prior to submission. Documents submitted with multiple layers will be flattened by the USPTO when converted to an image. Layers marked as "invisible" will be lost during conversion.

1078_EXACT SCIENCES 2023 FORM 10-K_NPL.pdf	151	Non Patent Literature	3383 KB
1_PETITION FOR IPR_NPL.pdf	90	Non Patent Literature	1399 KB
1026_COLOGUARD PATENT COVERAGE 2014_NPL.pdf	4	Non Patent Literature	431 KB
1025_COLOGUARD PATENT COVERAGE 2024_NPL.pdf	4	Non Patent Literature	860 KB
RNFOA 18179945 FILED 10- 06-2023_NPL.pdf	11	Non Patent Literature	735 KB
1076_COLOGUARD PATIENT GUIDE_NPL.pdf	34	Non Patent Literature	4481 KB

Warning: The PDF file contains multiple layers and must be flattened prior to submission. Documents submitted with multiple layers will be flattened by the USPTO when converted to an image. Layers marked as "invisible" will be lost during conversion.

USPTO_NFOA_18179945_N PL.pdf	7	Non Patent Literature	480 KB
---------------------------------	---	-----------------------	--------

Schroy_2005_NPL.pdf	7	Non Patent Literature	325 KB
Patent Owners SurReply.pdf	13	Non Patent Literature	184 KB
Vernon_1997_NPL.pdf	17	Non Patent Literature	553 KB
BEEKER_2000_NPL.pdf	16	Non Patent Literature	342 KB
DECLARATION OF D. WHITNEY_IPR202401330_N PL.pdf	225	Non Patent Literature	3114 KB
1029_RFOA 14145082 FILED 07-31-2015_NPL.pdf	123	Non Patent Literature	7850 KB
Patent Owners Response.pdf	71	Non Patent Literature	362 KB
Petitioners Response.pdf	13	Non Patent Literature	190 KB

Digest

DOCUMENT	MESSAGE DIGEST(SHA-512)
2024-10- 17_35239.313_ADS_FINAL.pdf	6B9DE7904A19FBF895FF9B592DF4E203BA784DF1633895C76 4643A561CFAE8C856BCE8AA27B9B9C682303DDB40A14D2A3 978F6F95A9BDA7C69D856B8B494F4CD
35239- 313_SEQUENCE_LISTING.xml	2E38E718DDC1DFE331CC63A0841A57943C4D890A25B71E32 B49493289DDAFBF6B5EE0390DE4C85DBF3E1510F09609CA0 338A34822E278530B5E78C7327E49359
2024-10- 17_35239.313_439.pdf	C6712E62241D0A31C507234E9DAD36EE3B5A0D03B92F89A32 98BDB8121D8CCDA1F727886C10EF8EDC01429622B1754B807 01F598B81657936E9D90EE40348329
2024-10- 17_35239.313_Exec_Decl.pdf	F4E816446026739CF274E7C2E136426C9CE270A41A10F6E5A E7EECE308CFC4C0A0E0C3F80970E8D5569641BB10D813E48 137F8E5E3996471B0BEB6A00ACF242B
2024-10- 15_35239.313_TRACK1.pdf	4EA6B83CE77A7D024A1F02C80678982DF2C8F8ED13116F299 2F2F24EB6247F9C24CB91360828AC105EDC4E18A9E324834F 6B0E082D306419174D71ABBA78904A
2024-10- 17_35239.313_EXEC_POA.pdf	A88717C511270AE05A344AF6E817D9BDCC78206113D78EBF4 27FC08BC72F045A5C3BC406AD0F4CB5203C429D45DFE524C 86B8B2EE32E254F38275C73D4C60F78
2024-10- 17_35239.313_IDS.pdf	98BA0D1C836CD7CCE08FF4C83A17A9137526C06B79047F8B 55885295FF16B82170E36B9E43D55DF12E9AE4675A6A5F62F A411826DB8F2D4C95F4138D66045E53
2024-07-	1529BA0253536C7B691AF9752C24ED5252C2B844F1F567C0F

26_35239.5511_Decision on IPR.pdf	66A4008DF848F87E88B55DF9E8FD215F856AE830F61F7557B9A064196877FC536073C9E39A0D043
2024-10-15_35239.313_APPLICATION.pdf	A84B37746479473D1F8B899185AA3E3C7B049364AD087EB89B6E5621DE9E631CDF4CDA60C92264F5C7121A8DEFDACA39B5A2796D0F002F1C4E5C847C1E789862
2024-10-15_35239.313_APPLICATION-SPEC.pdf	578ECEB02CF5369163420D7FF3497B7F1828314001BF91EF6C924994E4328640CC37BDBB0B6F8F7F120E26848E316FBC2375BDDB67C033568740F9F7EBD14ADA
2024-10-15_35239.313_APPLICATION-CLM.pdf	E3340611B1BCEA23204F3379791DF78D864003CCA20A899E349911415EBDC110E4D8775091A1A4DDA666E9C44C4FA22A32E656F5D7D70097105302B0EFD17DAD
2024-10-15_35239.313_APPLICATION-ABST.pdf	C9116BB86352D226E5B5E9F93647A86C92D17FF8F79015BD014B0AF9E177CC70D187470D01B57F53752560720D84347EBDC051AA3E5A4BB29F11E157FF58F2A7
ZOU_T1105_2008_NPL.pdf	96D929457F7BB5F0B46EE8989716E62E546B13F4B63A5DF0CBB878AF5D9B58BAF57E85BD8D355EE3C5CAF4B4451B8FC82056A06E2C72E68D4EC59B40E3EF276F
ZOU_T2034_2009_NPL.pdf	7B15B5E968B55C62E756181BF2325793F041837A224DD5E62F6B710AB06AF71990150DAA0DC84BDBC77B23C31721EC76F17367A22B17C25AE5EC28ECDFEC188C
ZOU_T2036_2009_NPL.pdf	A1351B06CA83D217C53B310F435B902F85D439A2E2A3A4C52D934F37EF7C2A50E442E38D2DE6337C2A1C0DBCAF27ABC38ECE917CA161B746370B581063983094
HARDISON_2005_NPL.pdf	EEC554C15FD9A5F0F4DB924B694C6053289BA7BA566EE1EFB17E7D57A896F8B6F71055A17318B6E2DBA36D22CE6A85A6B05D939C7A2585D81ADFFD325EAD6329
ZOU_T2037_2009_NPL.pdf	2632F3484ABC7EE29186FD546054384EA4ED23205048F796F6FE733EBD77F95A058239EA054AB13783D0F6CB1DDE50EEBBE22370668E03D48503431CE07E3E8C
WHITNEY_2004_NPL.pdf	DA4D8153EBC4FEF5E81A36D2F121769979A8D878B7DDFE432B8AB1FF93C651418D1AE64897610925140D91748F770D6F6EA43482CF4F414015D2133EC345366B
ITZKOWITZ_T1098_2008_NPL.pdf	89148713CD45AB8ED4DA69E2CF7B5E51B16AEFD78F68AC6A861DCE9A634B16B5DCA8BA61133AAF6E67862DAE2A91933CAC83FD6044CD8C74CFD375EEECA5C255
JIANG_T1102_2008_NPL.pdf	DBA0426B5BCA0E46300BCE6E6A13B4DF3F616A8B56E8379BD7ADDF71B3E3D58E6B28A2D61388F234BD8E29DFC15DBBF927DC6E14F3D5B7B860535161829EC84F
DOLLINGER_2008_NPL.pdf	F6B76769B00202084CF5F69E26F221BC346E6144614CD7FC1DD216ACBBDD56C73B5EBD9E37402F5C6263F1F678B5BCC678B387EC6F6AF2D11729F816ED0C0C09

OORT_2008_NPL.pdf	BEA9B6444166B579356D6157C38B24462817AE6AF5BA4E910 FEB5FE2BA6014AD8AAEDAC173F1EC780FFC49449E405F198 42322F0B977B9DA43DFF27AB4E9BECC
ZOU_GASTRO_2009_NPL.pdf	0672246F94036A9F3E6852F9EA68E7DA8CBF7EBE2B13BA4D A24D89A1790FA1A31F2DF70830C7EBB45BFCB2E9F3CC3DA2 4578CB52EAD0BB2EE71873D2DDCAF2C8
1083_JONES DECLARATION_NPL.pdf	003359AEC8D8904A89F65DEF31015E0CE2342D78561F6A369 0EB78D9333207C46976EB7A5C9391CE02261B3AD95C0EDA4 0D738198BB74933D3676D05ED9F0FE6
1080_COLOGUARD PHYSICIAN BROCHURE_NPL.pdf	18551AD7998F773D94190B359C00041F3E14E644F6559399761 B5E1DC0199C61DB7BB73DB96F5D10153E2CDFC61D75A1B73 9F69EE230713C586B2144B5805C52
1079_EXACT SCIENCES COLOGUARD WEB PAGE_NPL.pdf	AA4391F829E29C1E4B9854E717738E7FC649F4C7364A5FEB0 EB7B41A2183E475544EC8C2A3EA10DC90855D83B3A355F919 A36033945F954CF60C8D9851964AA2
1081_COLOGUARD INSTRUCTIONS FOR USE_NPL.pdf	D38EFA8AFF9E30FFC6A532F544A0DFE8B93A87A917B9607E9 C8B825330AF8469B8269AED2FF13EC12157ABBF21B48843E8 BE41451E04A458672F21A42F59FCBC
1077_IMPERIALE 2014_NPL.pdf	72794EB0ECD3D2C30DD5BEF3A8289A30DE4E31496FF0E810 53ED3D5CA4C557112F0691F90813CEB2016AA340FB9EBE8E3 071383AC86AAD7160F24D37468CCC79
1078_EXACT SCIENCES 2023 FORM 10-K_NPL.pdf	FB03FBF8F78D06089C9B4AA1910382811E1678750051AB3BC A565B514CF7A17DB3C57A82DC0587C797026398AAC361919F 52F73F0B87DC8049637DF4B05CD178
1_PETITION FOR IPR_NPL.pdf	FB063E3C7CBBB51BAB3CDE9660A03E514B56AC77AD136CB 418840D1DB1A2C748395582E2B9658D2E45525AD3BD82C55E 5A01DD1D055AB64FE0CAF430F900A65F
1026_COLOGUARD PATENT COVERAGE 2014_NPL.pdf	94845490C53CF77309D632698FA5566F5D6E0717087E7DE7B6 D7015890FB44224CF4F257F48AC3EBAA67AD8F774F89D9F4E E8F27E0C1C4383D352D947FDE5A15
1025_COLOGUARD PATENT COVERAGE 2024_NPL.pdf	FF0BB71A938B846B8652236723AC895E613DDD832F198E31C 066A0E79C1745DBAD04F525E0D4CC6C195C0E38D9C24872C 4D1CF2FB8BDD213F29D7A197B9776E0
RNFOA 18179945 FILED 10- 06-2023_NPL.pdf	B12E0C6C7EDA62F7DAB3E2F4659918622495F64CF6EEB6C0 331D88FEAA2CE498C105F6EFC65722984876129461D2138DA D2ACCE1AB5B4D5EF0C410BC700E2715
1076_COLOGUARD PATIENT GUIDE_NPL.pdf	6F64E77C080BE96BC5FB5FF43FCF518F7A2F621A56FF15EA9 F2D312649281D9391C79767B22F368C3AE26B240BE2320370D 7F01F525EC04828CDB1641F0321D9
USPTO_NFOA_18179945_NP L.pdf	BF118AD588DDF16EF7AA937346D5811A4A0BC0E8786322EF B7FB2655FF049DD7A2A4FEA408C644B20ECCCEF3A7105241

	49275652560B8BEC40B3D5C89082566A
Schroy_2005_NPL.pdf	7B747B35B179765550B132974D8D0337DDA8996D41E47A76F D6B0A418A294851A26E3E07FF90D94A3955B4710930B955599 C06DB39C34C6632DD5D2065B6D873
Patent Owners SurReply.pdf	E3C61453BEDE1CD274E171FB36012150C9B0E37D5324A0FE1 66B4DEDA8E2CB83F2528FD0D29C4C9435A02246038731B552 0B2BD03B2D31E888E65A2675EDD0EB
Vernon_1997_NPL.pdf	3F8C6FC630DE4EFE9CB219521EA793501CAE139497ECC20D 41AFBAEF6DCC98624E361A5E52C9848EDD5DF92B606A5B19 5E2A651DEB1192AAE223D29A2E5876AC
BEEKER_2000_NPL.pdf	324B171BE5D5A17E8CE18A4501087DA489C368826C5DC46D D53154B2ECD3A8F16146D9FA8350210A71937277503C3073D0 314522446A0AC1445CD8D5611C289A
DECLARATION OF D. WHITNEY_IPR202401330_NP L.pdf	6813E623A1CB127290F3B15D8EDBD228EAE6A486C61D04D0 34C848C46E7D0B664D9DA834416805AB3F2CA34B37D5BCCB AA5089E796929BE188F7468A93E1901E
1029_RFOA 14145082 FILED 07-31-2015_NPL.pdf	D988389D90697A4BA9ED479D277CA27B3E6B870C3C3E4734F C6476BE53CD34B08749D42F1009B3A8C1E066078BA4149298 16C1C6B0A76A85F920AE4A13F2D1E6
Patent Owners Response.pdf	32D33D1E70A58FBF6C7092D84D50EEB494894E791C076B751 2C118CF00243931B4A0B4977BAD0E311981B41B0F74E4A76E B0FBCA91BA94955F9A338180C77CCE
Petitioners Response.pdf	D443DE69D7D9A16F28118DB5EF8E2255ED6B7E88D2CA07B2 FE26F3DDD2D16F07AB0DAE7B1E7E8D7AF1453C396332B68D 9748CB1FDABFAA7E9F0AF913C9B8C72B

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.